

## Stephen Paul Fortmann Curriculum Vitae

**Current Positions:** C. F. Rehnborg Professor in Disease Prevention (Emeritus)  
Stanford University School of Medicine

Distinguished Investigator (Retired)  
Kaiser Permanente Center for Health Research

**Contact:** 28 NE Tillamook St Unit C  
Portland, Oregon 97212-4171, USA  
Mobile: +1 503-333-3428  
EM: [Fortmann@Stanford.edu](mailto:Fortmann@Stanford.edu); Personal: SPFortmann@icloud.com  
Web: [https://med.stanford.edu/profiles/Stephen\\_Fortmann/](https://med.stanford.edu/profiles/Stephen_Fortmann/)  
<https://research.kpchr.org/Research/Our-People/Emeritus-Investigators>

## Academic History

### 1. Education

1966-1970 Stanford University, A.B. (Biology)  
1970-1974 University of California, San Francisco, M.D.

### 2. Postdoctoral and Residency Training

#### **Santa Clara Valley Medical Center, San Jose, California**

1974-1975 Internship in Medicine and Pediatrics  
1975-1977 Residency in Medicine

#### **Stanford University School of Medicine, Stanford, California**

1977-1979 Research Fellow in Cardiovascular Disease Epidemiology and  
Prevention, Stanford Heart Disease Prevention Program  
1977-1979 Robert Wood Johnson Clinical Scholar  
1978 Fellow, Fourth U.S. Ten-Day Seminar on Cardiovascular Disease  
Epidemiology, American Heart Association

### 3. Board Certification and Licensure

1975 National Board of Medical Examiners  
1975– Physician and Surgeon Certificate, Medical Board of California  
(G29702) [Retired/Inactive status, GFE29702, 2010–]  
1977 American Board of Internal Medicine  
2012– Doctor of Medicine, Oregon Medical Board (MD157289) [expires  
12/31/2021]

### 4. Research (Current Support in Boldface) (64 grants total; 44 as PI or Co-PI/MPI; 40 NIH/AHRQ/HRSA/CDC; 20 RCTs]

1983–1986 PI: *Effects of Weight Loss on Ambulatory Blood Pressure in Man*;  
National Heart, Lung, and Blood Institute, (HL 31138)

- 1983–1992 Director and Co-PI: *Stanford Five-City Multifactor Risk Reduction Project*; National Heart, Lung, and Blood Institute (HL 21906)
- 1984–1990 PI: *Self-Help Smoking Cessation and Maintenance Study*; National Cancer Institute (CA 39303)
- 1988–1994 PI: *A Population-based Study of Cessation in Heavy Smokers*; National Heart, Lung, and Blood Institute (HL 39770)
- 1990–1991 PI: *Smoking Cessation for American Indians* (subcontract from Northern California Cancer Center)
- 1990–1991 PI: *Reducing the Illegal Sale of Tobacco to Minors*; Thrasher Research Fund
- 1991–1994 Co-PI: *Relating Tobacco Access and Consumption Among Youth*; California Tobacco-Related Disease Research Program (2RT0227)
- 1991–1997 PI: *Cardiovascular Disease Nutrition Education in Low Literate Adults*; National Heart, Lung, and Blood Institute (HL 46782)
- 1992–1997 PI: *Stanford Five-City Multifactor Risk Reduction Project*; National Heart, Lung, and Blood Institute (HL 21906)
- 1992–1996 PI: *Nicotine Patch Treatment for Smoking Relapse Prevention*; National Heart, Lung, and Blood Institute (HL 47219)
- 1992–2009 PI: *Cardiovascular Disease Prevention Training Program*; National Heart, Lung, and Blood Institute (HL 007034)
- 1994–1995 PI: *A Placebo-controlled Study Assessing the Safety and Relative Efficacy of High Dose Nicoderm*; ALZA Corporation
- 1995–2000 PI: *High Dose Nicotine Replacement for Heavy Smokers*; National Cancer Institute (CA 68968)
- 1995–2000 PI: *Smokeless Tobacco: Nicotine Patch Self-Help Treatment*, National Cancer Institute (CA 64285)
- 1997–1998 PI: *A 54-Week Open Label Assessment of the Safety and Efficacy of Atorvastatin*, Parke-Davis/Pfizer
- 1997–2000 PI: *Evaluation of the California Wellness Foundation Violence Prevention Initiative*, California Wellness Foundation
- 1997–2001 PI: *Policy Studies on Limiting Tobacco Marketing to Youth*, National Cancer Institute (CA 67850)
- 1997–2000 PI: *Environmental Influences on Adolescent Drinking: Community Support for Policy Solutions*, Robert Wood Johnson Foundation
- 1997–2000 Co-PI: *Nicotine Replacement and Paroxetine for Smoking Cessation*, California Tobacco-Related Disease Research Program (6RT-0041)
- 1998–2001 PI: *Reducing Provision of Tobacco to Minors from Social Sources*, California Tobacco-Related Disease Research Program (7RT-0156)
- 1998–2001 Co-PI: *Effects of Selegiline on Craving for Nicotine* (Killen) California Tobacco-Related Disease Research Program (7RT-0094)
- 2000–2003 PI: *Tests of the Tobacco Industry's Youth Smoking Prevention Ads*, California Tobacco-Related Disease Research Program (9RT-0138)
- 2000–2006 PI: *Genetic Epidemiology of Cardiovascular Disease and Healthy Aging*; a component of the Donald W. Reynolds Cardiovascular Clinical Research Center at Stanford University (M. Hlatky, PI)

- 2000–2004 Co-investigator: *Improving Adherence for Dyslipidemia and Anticoagulation* (Rudd), National Heart, Lung, and Blood Institute (HL66799)
- 2001–2004 Co-investigator: *Neighborhood Level Influences on All-Cause Mortality* (Winkleby) NIEHS/NHLBI (HL67731)
- 2001–2005 Co-PI: *Maintenance Treatment for Smoking Cessation* (Killen), National Cancer Institute (R01 CA90300)
- 2002–2021 Investigator (PI 2002-2010): *Impact of Retail Tobacco Advertising on Youth Smoking*, National Cancer Institute (R01 CA067850) [Henriksen, Lisa, Ph.D.].
- 2002–2005 Co-investigator: *National Trends in Outpatient Quality Indicators* (Stafford), Agency for Healthcare Research and Quality (HS11313)
- 2003–2007 Co-PI: *Behavioral Maintenance Treatment for Smoking Cessation* (Killen), National Institute on Drug Abuse (R01 DA01744)
- 2004–2006 PI: *The Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients with Dyslipidemia* (SEACOAST Study), Kos Pharmaceuticals, Inc.
- 2005–2009 Co-PI: *Selegiline Patch for Treatment of Nicotine Dependence* (Killen), National Institute on Drug Abuse
- 2005–2007 Investigator, *Effects of Outlet/Ad Density on Teen Smoking* (Henriksen), California Tobacco-Related Disease Research Program
- 2006–2009 Investigator, *Whole Genome Association for Early Coronary Artery Disease and Related Phenotypes* (Quertermous), National Heart, Lung, and Blood Institute (R01 HL087647)
- 2008–2012 Investigator (Co-PI 2008-2010), *Association of Outlet Density with Smoking and Pack Price* (Henriksen); California Tobacco-Related Disease Research Program (17RT-0152)
- 2009–2012 Investigator, *Modeling and Mapping Changes in Tobacco Outlet Density* (Henriksen); California Tobacco-Related Disease Research Program (18RT-0101)
- 2009–2013 Co-Principal Investigator, *Identifying Disparities in Type 2 Diabetes Among Asian Americans: The Pan Asian Cohort Study (PACS)* (Palaniappan), National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK081371)
- 2010–2017 Investigator, *Community Health Applied Research Network Central Data Management and Coordinating Center (CHARN)* (McBurnie), Health Resources and Services Administration (UB3 HA20236)
- 2011–2013 Systematic Review Lead, *Systematic Evidence Reviews to Support the U.S. Preventive Services Task Force* (Chou), Agency for Healthcare Research and Quality (HHS 290-2007-10057-1)
- 2011–2013 Co-investigator, *Cumulative Glycemic Burden and Cardiovascular Disease Risk in Type 2 Diabetes* (Nichols), National Institute of Diabetes and Digestive and Kidney Diseases (R21 DK091773)
- 2011–2015 Investigator, *Assessing a Medicaid Randomized Insurance Experiment within Community Clinics* (DeVoe), National Heart, Lung, and Blood Institute (R01 HL107647)

- 2012–2016 Co-investigator, *Understanding Disparities in Preventative Services for Patients with Mental Illness* (Green), National Institute of Mental Health (R01 MH096795)
- 2013–2017 Principal Investigator, *Centers for Education and Research on Therapeutics (CERTs) Scientific Forum*, Agency for Healthcare Research and Quality (U19 HS 021107)
- 2013–2018 Co-Investigator and Site Principal Investigator, *Hawaii Asian and Pacific Islander Diabetes Study (HAPI-D)*, National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK096021) [Waitzfelder, Beth, Ph.D.]
- 2013–2014 Co-Investigator, Tobacco Cessation, Systematic Evidence Reviews to Support to the U.S. Preventive Services Task Force (Whitlock, Evelyn), Agency for Healthcare Research and Quality (HHS 290-2012-00015-I)
- 2014–2023 Principal Investigator, *Health and Economic Effects of Light Rail Lines: A Natural Experiment*, National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK103385)
- 2014–2017 Principal Investigator, *Randomized Trial of Exercise in Primary Care*, National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK100900) [Multiple PI with Deborah R. Young]
- 2015–2025 Site Principal Investigator, *Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)*, National Institute of Diabetes and Digestive and Kidney Diseases (1U34DK088043) [National PI David M. Nathan]
- 2015–2016 Co-Investigator, The Economic Benefits of Triglyceride Lowering among Patients with Diabetes and Severe Hypertriglyceridemia, AstraZeneca (Nichols, Gregory A.)
- 2015–2017 Co-investigator and Site Principal Investigator, *Treatment of Hypertension In Adults with Thiazides: Pragmatic Trial Pilot Study*, National Heart, Lung, and Blood Institute (R34 HL119790) [Margolis, Karen, MD, PI]
- 2015–2025 Principal Investigator, *Cardiovascular Disease Among Asians and Pacific Islanders (CASPER)*, National Heart, Lung, and Blood Institute (R01 HL126172) [Multiple PI with Waitzfelder, Beth, PhD, and Palaniappan, Latha, MD]. This study is a collaboration of the Center for Health Research (CHR), CHR|Hawaii (Dr. Waitzfelder), Stanford Medical School (Dr. Latha Palaniappan), and the Palo Alto Medical Foundation Research Institute (PAMFRI) (Dr. Sukyung Chung)
- 2017–2022 Principal Investigator, *Evaluating the Implementation of Diabetes Prevention Program in an Integrated Health System*, National Institute of Diabetes and Digestive and Kidney Diseases (DK115237) [Multiple PI with Fitzpatrick, Stephanie, PhD]
- 2017–2018 Site Principal Investigator (Member of Steering Committee), *Advancing Geriatrics Infrastructure & Network Growth*, National Institute on Aging (AG 045050) [Gurwitz, Jerry H., MD, PI]
- 2018–2023 Site Principal Investigator (Member of Steering Committee), *Advancing Geriatrics Infrastructure & Network Growth*, National Institute on Aging (AG 057806) [Gurwitz, Jerry H., MD, PI]

2019–2025	Site Principal Investigator, <i>Spectrum-Stanford Center for Clinical and Translational Research and Education</i> (NCATS 1UL1 TR003142) [Ruth O’Hara, Stanford, Overall P.I.]
2019–2025	Co-Investigator and Site Principal Investigator, <i>Intervention based in Primary Care to Increase Physical Activity Among Inactive Adults with Prediabetes and Diabetes</i> (DK123053) [Young, Deborah Rohm, PI]
2019–2024	Co-Investigator and Site Principal Investigator, <i>Multimorbidity and Treatment-Related Outcomes in Older Heart Failure Patients</i> (NIA, AG062630) [Tisminetzky, Mayra, PI]
2020–2024	Co-Investigator and Site Principal Investigator, <i>PROMISE: PREventing Obesity through healthy Maternal gestational weight gain In the Safety nEt</i> (R01DK118484) [Boone-Heinonen, Janne, PI]
2020	Sub-Investigator, <i>A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 and (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment.</i> (Gilead Sciences Inc.) [Mularski, Richard A., PI]
2020–2021	Co-Investigator, <i>A Multicenter, Adaptive, Randomized, Blinded, Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT)</i> (NIAID) [Mularski, Richard A., PI]
2020–2024	Co-Investigator and Site PI, <i>Potential for Repurposing Currently Approved Medications to Fight COVID-19: A Proof-of-Concept Study.</i> (Garfield Foundation) [Dublin, Sascha, PI]
2020–2021	Co-Investigator, <i>Reduced Red Blood Counts in Older Heart failure patients: Evaluation and Related Treatment (RBC HEART) Study: A Pragmatic Randomized Clinical Trial, Pilot</i> (U01AG034661); a component of PACTTE-Partnership for Anemia: Clinical and Translational Trials in the Elderly (NIA) [Cohen, Harvey, PI]
2020–2023	Site Principal Investigator, <i>A Phase 2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals</i> (C4591001) (Pfizer)
2020–2022	Co-Investigator and Medical Director, <i>RECOVER: Expanded Second Wave of Recruitment for SARS-CoV-2 Vaccine Effectiveness Analysis</i> (CDC, 75D30120C08150, Edwards, Laura, PI)
2020–2024	Co-Investigator, <i>Long Term Immunity Following Yellow Fever Vaccination</i> (NIAID, AI145835) [Messer, William, PI]
2021–2024	Site Principal Investigator, <i>A Phase 3 Master Protocol to Evaluate Additional Dose(S) of BNT162b2 in Healthy Individuals Previously Vaccinated with BNT162b2</i> (C4591031) (Pfizer)
2021–2024	Co-Investigator, <i>CASCADIA: Prospective Observational Cohort Study to Assess SARS-Cov-2 Vaccine Effectiveness in Children and Adults</i> (CDC 75D30121C12297)[Naleway, Allison, PI]
2022–2025	Principal Investigator, <i>An Interventional, Randomized, Active-Controlled, Phase 2/3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b RNA-Based Vaccine Candidates</i>

2023–2025 *as a Booster Dose in Covid-19 Vaccine–Experienced Healthy Individuals* (C4591044) (Pfizer)  
 Site Principal Investigator, *Tufts Clinical and Translational Science Institute* (NCATS UM1 TR004398) [Selker, Harry, Overall P.I.]

## Employment History

### **Stanford University School of Medicine, Stanford, California (1979–2010)**

1979–1982 Physician Specialist and Clinical Instructor, Department of Medicine  
 1979–1982 Director of Community Studies, Stanford Heart Disease Prevention Program  
 1983–1987 Co-Director, Cardiovascular Disease Epidemiology and Prevention Training Program  
 1983–1988 Associate Director, Stanford Center for Research in Disease Prevention  
 1983–1989 Assistant Professor of Medicine  
 Assistant Professor of Epidemiology (by courtesy)  
 1983–1989 Co-Director, Stanford Preventive Medicine Clinic  
 1987–2010 Director, Cardiovascular Disease Epidemiology and Prevention Training Program, PI: Cardiovascular Disease Prevention Training Program, National Heart, Lung, and Blood Institute (5 T32 HL 007034; 1987–2011)  
 1988–1997 Deputy Director, Stanford Center for Research in Disease Prevention  
 1988–1996 Head, Section on Clinical Epidemiology and Disease Prevention, Division of General Internal Medicine  
 1990–2010 Director, Preventive Cardiology Clinic, Division of Cardiovascular Medicine  
 1990–1995 Associate Professor of Medicine (Clinical)  
 Associate Professor of Health Research and Policy (Epidemiology) (by courtesy)  
 1995–1999 Associate Professor of Medicine  
 Associate Professor of Health Research and Policy (Epidemiology) (by courtesy)  
 1998–2010 Director, Stanford Prevention Research Center (formerly Center for Research in Disease Prevention)  
 1999–2010 C. F. Rehnberg Professor in Disease Prevention, Department of Medicine  
 1999–2010 Professor of Medicine (General Internal Medicine)  
 1999–2010 Professor of Health Research and Policy (Epidemiology) (by courtesy)  
 2010– C. F. Rehnberg Professor in Disease Prevention in the School of Medicine (Emeritus)

**Kaiser Permanente Center for Health Research (2010–)**

2010–2018	Senior Investigator, Science Programs Department
2010–2017	Assistant Program Director, Science Programs Department
2016–2017	Interim Director, Center for Health Research
2017–2025	Senior Director, Science Programs
2018–2025	Distinguished Investigator, Science Programs Department
2022–2024	Interim Director of CHR, Interim Vice President for Research, Kaiser Permanente Northwest

**Oregon Health and Science University (2012–)**

2012–2018	Affiliate Professor of Public Health and Preventive Medicine
2018–2025	Affiliate Professor, Oregon Health and Science University – Portland State University   School of Public Health

**Kaiser Permanente Bernard J. Tyson School of Medicine (2020–)**

2020–2025	Professor of Health Systems Science
-----------	-------------------------------------

## Public and Professional Service

**Committees**International

1982–1985	Chairman, Steering Committee of the World Health Organization MONICA Project
1993–1997	Organizing Committee of the Fourth International Conference on Preventive Cardiology
1993–1998	Leader, Main Results Writing Group, World Health Organization MONICA Project

National/Regional

1979–1982	Member, Criteria and Methods Committee, American Heart Association Council on Epidemiology and Prevention
1980–1990	Coordinating Committee for Community Demonstration Studies, National Heart, Lung, and Blood Institute
1985–1988	Chairman, Criteria and Methods Committee, American Heart Association Council on Epidemiology and Prevention
1985–1988	Consultant, National Center for Health Statistics (advised on development of the tenth revision of the International Classification of Diseases).
1987–2002	Member, Policy Board, Atherosclerosis Risk in Communities Study, National Heart, Lung, and Blood Institute
1988–1989	California Chronic and Sentinel Disease Surveillance Program Task Force; Department of Health Services, State of California

1988–1990	Epidemiology Advisory Group, American Cancer Society, California Division
1988–1990	Executive Committee, American Heart Association Council on Epidemiology
1989	Ad hoc Committee on Hypertension Prevention and Control, Department of Health Services, State of California
1989	Tobacco Research Working Group, Northern California Cancer Center
1989–1990	Scientific Advisory Committee: Detection, Prevention, and Education Program, Northern California Cancer Center
1991–1992	Research Committee, California Affiliate of the American Heart Association
1991–1992	Program Committee, American Heart Association Council on Epidemiology and Prevention
1992–1994	Chairman, Program Committee, American Heart Association Council on Epidemiology and Prevention
1992–1994	Vice-Chairman, American Heart Association Council on Epidemiology and Prevention
1994–1996	Chairman, American Heart Association Council on Epidemiology and Prevention
1996	Chairman, Special Emphasis Panel on Cardiovascular Disease Surveillance, National Heart, Lung, and Blood Institute
1996–2006	Member, Special Ad Hoc Working Group for the Women’s Health Initiative of the Advisory Committee on Research on Women’s Health, Office on Research on Women’s Health, Office of the Director, National Institutes of Health.
1996	Member, Research Committee, California Affiliate of the American Heart Association
1997	Member, Behavioral Science, Epidemiology, and Prevention Review Committee, American Heart Association National Center
1998	Program Chair, 50 <sup>th</sup> Anniversary Research Conference, National Heart, Lung, and Blood Institute
1998–2001	Chair, Committee on Epidemiologic Statistics, American Heart Association, Council on Epidemiology and Prevention
1999	Member, Planning Committee, Conference on Cardiovascular Disease Trends, National Heart, Lung, and Blood Institute
1999–2001	Member and Vice-Chair, Population Science Committee, American Heart Association National Center
2001	Member, Task Force on the Prevention of Cardiovascular Disease, National Heart, Lung, and Blood Institute
2001–2003	Chair, Population Science Committee, American Heart Association National Center
2001–2003	Member, Science Advisory and Coordinating Committee, American Heart Association National Center
2002	Member, Program Committee, “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Application to

	Clinical and Public Health Practice;” American Heart Association and Centers for Disease Control and Prevention
2002	Member, Program Committee, “Workshop on Myocardial Infarction Criteria;” American Heart Association, National Heart, Lung, and Blood Institute, and Centers for Disease Control and Prevention, 28-29 May 2002
2002	Chair, Protocol Review Committee, Trial of Activity for Adolescent Girls (TAAG), National Heart, Lung, and Blood Institute, 18 July 2002
2003–2006	Chair, Data Safety and Monitoring Board, Trial of Activity for Adolescent Girls (TAAG), National Heart, Lung, and Blood Institute
2010–2012	Member, Cardiovascular and Sleep Epidemiology Study Section, Center for Scientific Review, National Institutes of Health
2010–2014	Member, Data Safety and Monitoring Board, <b>E</b> arly <b>A</b> dult <b>R</b> eduction of <b>W</b> eight <b>T</b> hrough <b>L</b> ifest <b>Y</b> le <b>I</b> ntervention ( <b>E</b> ARLY) Trials, National Heart, Lung, and Blood Institute
2012–2014	Chair, Cardiovascular and Sleep Epidemiology Study Section, Center for Scientific Review, National Institutes of Health
2016–2017	Member, External Expert Panel, Prevention of Lower Urinary Tract Symptoms in Women, National Institute of Diabetes and Digestive and Kidney Diseases

#### Stanford University

1996–1997	Member, Advisory Panel on Investment Responsibility
1997–1998	Chair, Advisory Panel on Investment Responsibility
1997–1998	Member, Special Committee on Investment Responsibility, Board of Trustees (ex officio)
2002–2006	Senator, University Faculty Senate (elected)
2003–2006	Member, Committee on Academic Computing and Information Systems, University Senate
2004–2006	Member, Systems Governance Group, Office of the Vice President for Business Affairs
2006–2008	Member, Sustainability Working Group
2009–2010	Affiliated Faculty, Woods Institute on the Environment

#### Stanford University School of Medicine

1996–1997	Clinical Trials Center Working Group
1996	Research Sub-committee, LCME Self-Study
2001–2002	Clinical Research Task Force
2003–2007	Executive Committee, Stanford Cardiovascular Institute
2007–2009	Steering Committee, Stanford Cardiovascular Institute

#### Stanford University Department of Medicine

1988–2002	Executive Committee, Division of General Internal Medicine
1988–1995	Chair, Medical Service Credentials Committee
1988–1995	Medical Service Steering Committee

1997–2007	Department of Medicine Leadership Group
1997–2009	Department of Medicine Division Chiefs
2001	Chair, Ad hoc Committee on the Operating Budget

#### Kaiser Permanente Center for Health Research

2010–2025	Member, Science Program Department Leadership Team
2010–2012	Member, CHR Joint Leadership Team
2012–2025	Member, CHR Leadership Team
2013–2016	Member, Population Strategy Group, Kaiser Permanente Northwest
2015	Member, Pre-Diabetes/Weight Management One-Stop Work Group, Kaiser Permanente Northwest
2015–2016	Chair, CHR Director Search Committee
2016–2020	Member, Access Review Committee, Kaiser Permanente Research Bank

#### **Editorships:**

1980–1984	Area Editor (Epidemiology), <i>Behavioral Medicine Abstracts</i>
1996–1998	Member, Editorial Board, <i>Cardiovascular Risk Factors: An International Journal</i> .
2006–2012	Member, Editorial Board, <i>Current Cardiovascular Risk Reports</i>

#### **Recent Reviewer Service (past 2 years):**

*Journal of the American Medical Association*  
*American Journal of Epidemiology*  
*Annals of Internal Medicine*  
*Circulation*

## Honors and Awards

#### **Honors:**

2005	Joseph E. Stokes, III, M.D., Preventive Cardiology Award, American Society for Preventive Cardiology
2005	Elected Member, National Academy of Medicine (formerly Institute of Medicine)

#### **Fellowships:**

1983	Fellow, Society for Behavioral Medicine
1984	Fellow, American Heart Association (Council on Epidemiology and Prevention)
1987	Fellow, American College of Physicians
1988	Fellow, American College of Epidemiology

#### **Memberships:**

1968–	American Association for the Advancement of Science
1977–	American College of Physicians

1978–2004	American Public Health Association
1978–	American Heart Association Council on Epidemiology and Prevention
1979–	Society for Epidemiologic Research
1982–	Society for General Internal Medicine
1982–	Society for Behavioral Medicine
1983–2002	American Federation for Medical Research
2000–	Society for Research on Nicotine and Tobacco
2000–	American Heart Association Council on Lifestyle and Cardiometabolic Health (formerly the Council on Nutrition, Physical Activity, and Metabolism: 2000-2013)
2009–	Society for Clinical and Translational Science

### **Major Invited Papers and Addresses (selected from a total of 28)**

Fourth International Conference on Preventive Cardiology, Montreal, Canada, 2 July 1997  
*Are Preventive Efforts Effective in Populations with Low Socio-economic Status?*

American Heart Association 70<sup>th</sup> Scientific Sessions, Orlando, FL, 9 November 1997  
*Measuring Non-traditional Risk Factors: How Much Does It Add?*

National Conference on Cardiovascular Disease Prevention: Meeting the Healthy People 2010 Objectives for Cardiovascular Health. National Heart, Lung, and Blood Institute, Bethesda, MD; 27-29 September 1999.  
*Trends in Implementation of Population-wide Interventions to Promote Healthy Lifestyles*

American Heart Association 72<sup>nd</sup> Scientific Sessions, Atlanta, GA; 7-10 November 1999;  
 Program on Motivation and Adherence for Cardiovascular Risk Factor Reduction  
*Smoking Cessation Interventions*

Community Prevention Research in Women's Health Conference. Centers for Disease Control and Prevention and the National Heart, Lung, and Blood Institute, Bethesda, MD, 26-27 October 2000  
*Cardiovascular Disease Studies: Analysis and Discussion*

American Heart Association 74<sup>th</sup> Scientific Sessions, Anaheim, CA, 14 November 2001;  
 Beyond Statins, Beta-Blockers, and ACE Inhibitors: Added Benefits of Lifestyle Modifications on Coronary Risk Reduction  
*Smoking Cessation*

Workshop on Criteria for Acute Myocardial Infarction for Epidemiological Studies; American Heart Association Council on Epidemiology and Prevention and National Heart, Lung, and Blood Institute; Airlie Conference Center, Virginia; 28–29 May 2002  
*Criteria Used in the U.S. Community CVD Prevention Studies*

National Institutes of Health Pathways to Prevention Workshop: Methods for Evaluating Natural Experiments in Obesity. Natcher Conference Center, NIH Campus, 5–6 December 2017.  
*Linking Health System, Environmental, and Contextual Data for Evaluation of Natural Experiments: Lessons Learned*

## Scholarly Publications

### 1. Peer-reviewed articles

1. Williams PT, **Fortmann SP**, Farquhar JW, Varady A, Mellen S. A comparison of statistical methods for evaluating risk factor changes in community-based studies: an example from the Stanford Three Community Study. *J Chron Dis* 1981;34:565-571. PMID: 7287861
2. **Fortmann SP**, Marcuson R, Bitter PH, Haskell WL. A comparison of the Sphygmometrics SR-2 automatic blood pressure recorder to the mercury sphygmomanometer in population studies. *Am J Epidemiol* 1981;114:836-844. PMID: 7315832
3. **Fortmann SP**, Williams PT, Hulley SB, Haskell WL, Farquhar JW. Effect of health education on dietary behavior: The Stanford Three Community Study. *Am J Clin Nutr* 1981;34:2030-2038. PMID: 7293934
4. **Fortmann SP**, Williams PT, Hulley SB, Maccoby N, Farquhar JW. Does dietary health education reach only the privileged? An answer from the Stanford Three Community Study. *Circulation* 1982;66:77-82. PMID: 7083524
5. Taylor CB, **Fortmann SP**. Essential hypertension. Psychosomatic illness review: No. 9 in a series. *Psychosomatics* 1983;24:433-448. PMID: 6878599
6. **Fortmann SP**, Haskell WL, Vranizan K, Brown BW. The association of blood pressure and dietary alcohol: differences by age, sex, and estrogen use. *Am J Epidemiol* 1983;118:497-507. PMID: 6637977
7. Gillum RF, **Fortmann SP**, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. *Am Heart J* 1984;108:150-8. PMID: 6731265
8. **Fortmann SP**, Rogers T, Haskell WL, Solomon DS, Vranizan K, Farquhar JW. Indirect measures of cigarette use: expired air carbon monoxide vs. plasma thiocyanate. *Prev Med* 1984;13:127-34. PMID: 6609353
9. Jacob RG, **Fortmann SP**, Kraemer HC, Farquhar JW, Agras WS. Combining behavioral treatments to reduce blood pressure: a controlled outcome study. *Behavior Modification* 1985;9:32-54. PMID: 3977813
10. Sallis JF, Haskell WL, Wood PD, **Fortmann SP**, Rogers T, Blair SN, Paffenbarger RS. Physical activity assessment methodology in the Five-City Project. *Am J Epidemiol* 1985;121:91-106. PMID: 3964995
11. **Fortmann SP**, Sallis JF, Magnus PM, Farquhar JW. Attitudes and practices of physicians regarding hypertension and smoking: The Stanford Five-City Project. *Prev Med* 1985;14:70-80. PMID: 4034516
12. Sallis JF, Flora JA, **Fortmann SP**, Taylor CB, Maccoby N. Mediated smoking cessation programs in the Stanford Five-City Project. *Addictive Behaviors* 1985;10:441-443. PMID: 4091078
13. Farquhar JW, **Fortmann SP**, Maccoby N, Haskell WL, Williams PT, Flora JA, Taylor CB, Brown BW, Solomon DS, Hulley SB. The Stanford Five-City Project: Design and methods. *Am J Epidemiol* 1985; 122:323-34. PMID: 4014215

14. Sallis JF, Haskell WL, Wood PD, **Fortmann SP**, Vranizan KM. Vigorous physical activity and cardiovascular risk factors in young adults. *J Chron Dis* 1986;39:115-120. PMID: 3484748
15. **Fortmann SP**, Haskell WL, Williams PT, Varady AN, Hulley SB, Farquhar JW. Community surveillance of cardiovascular diseases in the Stanford Five-City Project: Methods and initial experience. *Am J Epidemiol* 1986;123:656-69. PMID: 3953544
16. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell S, Bacchetti P, **Fortmann SP**. Consequences of worksite hypertension screening. Differential changes in psychosocial function. *The American Journal of Medicine* 1986;80:853-860. PMID: 3706373
17. **Fortmann SP**, Haskell WL, Rennert MP, Williams PT, Farquhar JW. Changes in plasma high-density lipoprotein cholesterol after changes in cigarette use. *Am J Epidemiol* 1986;124:706-710. PMID: 3752064
18. Sallis JF, Haskell WL, **Fortmann SP**, Wood PD, Vranizan KM. Moderate intensity physical activity and cardiovascular risk factors: The Stanford Five-City Project. *Prev Med* 1986;15:561-568. PMID: 3797388
19. Sallis JF, Haskell WL, **Fortmann SP**, Vranizan KM, Taylor CB, Solomon DS. Predictors of adoption and maintenance of physical activity in a community sample. *Prev Med* 1986;15:331-341. PMID: 3763558
20. Sallis JF, Hill RD, Killen JD, Telch MJ, Flora JA, Girard J, Taylor CB, **Fortmann SP**. Efficacy of self-help behavior modification materials in smoking cessation. *Am J Prev Med* 1986;2:342-344. PMID: 3453200
21. Altman GA, Flora JA, **Fortmann SP**, Farquhar JW. The cost-effectiveness of three smoking cessation programs. *Am J Public Health* 1987;77: 162-165. PMID: 3099586; PMIC1646823
22. Maron DJ, **Fortmann SP**. Nicotine yield and measures of cigarette smoke exposure in a large population: Are lower-yield cigarettes safer? *Am J Public Health* 1987;77:546-549. PMID: 3565645; PMC1647026
23. King AC, Flora JA, **Fortmann SP**, Taylor CB. Smokers' challenge: Immediate and long-term findings of a community smoking cessation contest. *Am J Public Health* 1987;77:1340-1341. PMID: 3631371; PMC1647120
24. Williams PT, **Fortmann SP**, Terry RB, Garay SC, Vranizan KM, Ellsworth N, Wood PD. Associations of dietary fat, regional adiposity, and blood pressure in men. *JAMA* 1987;257:3251-3256. PMID: 3586249; PMC2831870
25. Rudd P, Price MG, Graham LE, Beilstein BA, Tarbell SJH, Bachetti P, **Fortmann SP**. Consequences of worksite hypertension screening: Changes in absenteeism. *Hypertension* 1987;10:425-436. PMID: 3653971
26. Principal Investigators of the MONICA Project WHO MONICA Project: Geographic variation in mortality from cardiovascular diseases. Baseline data on selected population characteristics and cardiovascular mortality. *World Health Statistics Quarterly* 1987;40:171-184. PMID: 3617777
27. WHO MONICA Project Principal Investigators (prepared by Tunstall-Pedoe, H). The World Health Organization MONICA Project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. *J Clin Epidemiol* 1988;41:105-114. PMID: 3335877

28. **Fortmann SP**, Haskell WL, Wood PD. Effects of weight loss on clinic and ambulatory blood pressure in normotensive men. *Am J Cardiol* 1988;62:89-93. PMID: 3381757
29. **Fortmann SP**, Killen JD, Telch MJ, Newman B. Minimal contact treatment for smoking cessation: A placebo-controlled trial of nicotine polacrilex and self-directed relapse prevention. *JAMA* 1988; 260:1575-1580. PMID: 3045351
30. Killen JD, **Fortmann SP**, Telch MJ, Newman B. Are heavy smokers different from light smokers? A comparison after 48 hours without cigarettes. *JAMA* 1988; 260:1581-1585. PMID: 3411738
31. Wood PD, Haskell WL, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko RS, **Fortmann SP**, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 1988; 319:1173-9. PMID: 3173455
32. The WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35-64 years. *World Health Stat Q* 1988;41:115-140. PMID: 3232405
33. Winkleby MA, **Fortmann SP**, Barrett DC. Social class disparities in risk factors for disease: eight-year prevalence patterns by level of education. *Prev Med* 1990;19:1-12. PMID: 2320553
34. Killen JD, **Fortmann SP**, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *J Consult Clin Psych* 1990;58:85-92. PMID: 2319049
35. Albright CL, Flora JA, **Fortmann SP**. Restaurant menu labeling: Impact of nutrition information on entree sales and patron attitudes. *Health Education Quarterly [now Health Education & Behavior]*, 1990;17:157-167. PMID 2347693
36. Farquhar JW, **Fortmann SP**, Flora JA, Taylor CB, Haskell WL, Williams PT, Maccoby N, Wood PD. Effects of community-wide education on cardiovascular disease risk factors. The Stanford Five-City Project *JAMA* 1990;264:359-365. PMID: 2362332
37. Killen JD, **Fortmann SP**, Newman B. Weight change among participants in a large sample minimal contact smoking relapse prevention trial. *Addictive Behaviors*, 1990;15:323-332. PMID: 2248106
38. **Fortmann SP**, Winkleby MA, Flora JA, Haskell WL, Taylor CB. Effect of long-term community health education on blood pressure and hypertension control: The Stanford Five-City Project. *Am J Epidemiol*, 1990;132:629-646. PMID: 2403104
39. Jackson C, Winkleby M, Flora J, **Fortmann SP**. Use of educational resources for cardiovascular risk reduction in the Stanford Five-City Project. *Am J Prev Med*. 1991;7:82-88. PMID: 1910892
40. Taylor CB, **Fortmann SP**, Flora JA, Kayman S, Barrett DC, Jatulis DE, Farquhar JW. Effect of long-term community health education on body mass index: The Five-City Project. *Am J Epidemiol* 1991;134:235-249. PMID: 1877583
41. Killen JD, **Fortmann SP**, Newman B, Varady A. Prospective study of factors influencing the development of craving associated with smoking cessation. *Psychopharm*, 1991;105:191-196. PMID: 1796127

42. Transdermal Nicotine Study Group [Christen A, Beiswanger B, Mau M, Walker C, Hatsukami D, Allen S, Huber M, Jensen J, Rennard S, Daughton D, Cheney R, Hatlelid K, Thompson A, Lichtenstein E, Biglan A, Ochs L, Heatley S, Repsher L, Schones W, Stillman D, Casey C, Poole B, Leitch J, **Fortmann S**, Killen J, Hansen M, Douss LR, Hughes J, Valliere W, Solomon L, Wadland W, Glover E, Glover P, Causey D, Knowles M, Vossroberts K, Prather D, Trunnell N, Moos D, Rolf C, Nowak R, Ackerman P, Malone N, Knowles M. Transdermal nicotine for smoking cessation: Six-month results from two multicenter controlled clinical trials. *JAMA-Journal of the American Medical Association* 1991; 266:3133-8. doi:10.1001/jama.1991.03470220049025. PMID: 1956099
43. Frank E, Winkleby MA, Altman DG, Rockhill B, **Fortmann SP**. Predictors of physicians' smoking cessation advice. *JAMA* 1991;266:3139-3144. PMID: 1956100
44. Jackson C, Jatulis DE, **Fortmann SP**. The behavioral risk factor survey and the Stanford Five-City Project Survey: A comparison of cardiovascular risk behavior estimates. *Am J Public Health*, 1992;82:412-416. PMID: 1536358; PMC1694372
45. Hyman DJ, Barrett DC, **Fortmann SP**. Effect of minor illness on serum cholesterol. *Am J Prev Med*, 1992;8:100-103. PMID: 1599716
46. Hyman DJ, Maibach EW, Flora JA, **Fortmann SP**. Cholesterol treatment practices of primary care physicians. *Public Health Reports* 1992;107:441-448. PMID: 1641441; PMC1403675
47. Winkleby MA, Jatulis DE, Frank E, **Fortmann SP**. Socioeconomic status and health: Comparing the contributions of education, income, and occupation to cardiovascular disease risk factors. *Am J Public Health* 1992; 82:816-820. PMID: 1585961; PMC1694190
48. Albright CL, Farquhar JW, **Fortmann SP**, Sachs DPL, Owens D, Gottlieb L, Stratos GA, Bergen MR, Skeff KM. Impact of a clinical preventive medicine curriculum for primary care faculty: Results of a dissemination model. *Prev Med* 1992;21:419-435. PMID: 1409485
49. Frank E, Winkleby MA, Rockhill B, **Fortmann SP**, Farquhar JW. Improved cholesterol-related knowledge and behavior and plasma cholesterol levels in adults during the 1980s. *JAMA* 1992;268:1566-1572. PMID: 1518111
50. Killen JD, **Fortmann SP**, Kraemer HC, Varady A, Newman B. Who will relapse? Symptoms of nicotine dependence predict long-term relapse following smoking cessation. *J Consult Clin Psych* 1992;60:797-801. PMID: 1401396
51. Winkleby MA, Rockhill B, Jatulis D, **Fortmann SP**. The medical origins of homelessness. *Am J Public Health* 1992;82:1394-1398. PMID: 1415869; PMC1695873
52. Altman DG, Linzer J, Kropp R, Descheemaeker N, Feighery E, **Fortmann SP**. Policy alternatives for reducing sales to minors: Results from a national survey of retail chain and franchise stores. *J Public Health Policy* 1992; 13:318-331. PMID: 1401050
53. Winkleby MA, **Fortmann SP**, Rockhill B. Trends in cardiovascular disease risk factors by educational level: The Stanford Five-City Project. *Prev Med* 1992;21:592-601. PMID: 1438109
54. **Fortmann SP**, Taylor CB, Flora JA, Jatulis DE. Changes in adult cigarette smoking prevalence after five years of community health education: The Stanford Five-City Project. *Am J Epidemiol* 1993;137:82-96. PMID: 8434576

55. Frank E, Winkleby MA, **Fortmann SP**, Farquhar JW. Cardiovascular disease risk factors: Improvements in knowledge and behavior in the 1980s. *Am J Public Health* 1993;83:590-593. PMID: 8460744; PMC1694478
56. Winkleby MA, **Fortmann SP**. Cigarette smoking trends in adolescents and young adults: The Stanford Five-City Project. *Prev Med* 1993;22:325-334. PMID: 8327416
57. Frank E, Winkleby MA, **Fortmann SP**, Rockhill B, Farquhar JW. Improvements in cholesterol-related knowledge and behavior and plasma cholesterol levels in youths during the 1980s. *Am J Public Health* 1993;9:168-174. PMID: 8347368
58. **Fortmann SP**, Taylor CB, Flora JA, Winkleby MA. Effect of community health education on plasma cholesterol levels and diet: The Stanford Five-City Project. *Am J Epidemiol* 1993;137:1039-1055. PMID: 8317434
59. Williams EL, Winkleby MA, **Fortmann SP**. Changes in coronary heart disease risk factors in the 1980's: Evidence of a male/female crossover effect with age. *Am J Epidemiol* 1993;137:1056-1067. PMID: 8317435
60. Frank E, **Fortmann SP**. The effects of smoking cessation on cardiovascular disease risk. *Cardiovascular Risk Factors* 1993;3:253-259. [No PMID or PMCID]
61. Winkleby MA, **Fortmann SP**, Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics. The Stanford Five-City Project. *Am J Epidemiol* 1993;137:1365-1375. PMID: 8333418
62. Jarvik M, Killen JD, Varady A, **Fortmann SP**. The favorite cigarette of the day. *J Behavioral Med* 1993;16:413-422. PMID: 8411146
63. Young DR, Haskell WL, Jatulis DE, **Fortmann SP**. Associations between changes in physical activity and risk factors for coronary heart disease in a community-based sample of men and women: The Stanford Five-City Project. *Am J Epidemiol* 1993;138:205-216. PMID: 8356962
64. Tribble DL, Giuliano LJ, **Fortmann SP**. Reduced plasma ascorbic acid concentrations in nonsmokers regularly exposed to environmental tobacco smoke. *Am J Clin Nutr* 1993;58:886-890. PMID 8249873
65. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease [Rennard S, Daughton D, Cheney R, Thompson A, Miles R, Windle J, Repsher L, Clifford DP, Schones W, **Fortmann SP**, Killen JD, Petty TL, Snyder J, Hamilton R, Williamson JW, Nett LM, Prochazka AV, Silvers W, Causey D, Prather D, Pardo B, Knowles M, Gupta S, Rolf C. Nicotine-replacement therapy for patients with coronary artery disease. *Arch Intern Med* 1994;154:989-995. doi: 10.1001/archinte.1994.00420090063007. PMID: 8179456
66. **Fortmann SP**, Killen JD. Who shall quit? Comparison of volunteer and population-based recruitment in two minimal-contact smoking cessation studies. *Am J Epidemiol* 1994;140:39-51. PMID: 8017402
67. WHO MONICA Project, Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: Registration procedures, event rates and case fatality in 38 populations from 21 countries in 4 continents. *Circulation* 1994; 90:583-612. PMID: 8026046

68. Jackson C, **Fortmann SP**, Flora J, Melton R, Snider JP, Littlefield D. The capacity-building approach to intervention maintenance implemented by the Stanford Five-City Project. *Health Educ Res* 1994; 9:385-396. PMID: 10150455
69. Killen JD, **Fortmann SP**. The role of nicotine dependence in smoking relapse: Results from a prospective study using population-based recruitment methodology. *Int J Behav Med* 1994; 1:320-334. PMID: 16250793
70. Allen SS, Hatsukami D, Gorsline J, Christen A, Rennard S, Heatley S, **Fortmann S**, Hughes J, Glover E, Repsher L, Lichtenstein E, Rolf CN. Cholesterol changes in smoking cessation using the transdermal nicotine system. *Prev Med* 1994; 23(2):190-196. doi: 10.1006/pmed.1994.1026. PMID: 8047525
71. Winkleby MA, Albright CL, Howard-Pitney B, Lin J, **Fortmann SP**. Hispanic/white differences in dietary intake among low educated adults and children. *Prev Med* 1994; 23:465-473. PMID: 7971874
72. Taylor CB, Jatulis DE, **Fortmann SP**, Kraemer HC. Weight variability effects: a prospective analysis from the Stanford Five-City Project. *Am J Epidemiol* 1995; 141:461-465. PMID: 7879790
73. **Fortmann SP**, Killen JK. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. *J Consult Clin Psych* 1995; 63:460-468. PMID: 7608359
74. Wild SH, Laws A, **Fortmann SP**, Varady AN, Byrne CD. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. *Ann Epidemiol* 1995; 5:432-439. PMID: 8680605
75. Winkleby MA, Schooler C, Kraemer HC, Lin J, **Fortmann SP**. Hispanic versus White smoking patterns by sex and level of education. *Am J Epidemiol* 1995; 142:410-418. PMID: 7625406
76. **Fortmann SP**, Flora JA, Winkleby MA, Schooler C, Taylor CB, Farquhar JW. Community intervention trials: Reflection on the Stanford Five-City Project Experience. *Am J Epidemiol* 1995; 142:576-86. PMID: 7653465
77. Young DR, Haskell WL, Taylor CB, **Fortmann SP**. Effect of community health education on physical activity knowledge, attitudes, and behavior: The Stanford Five-City Project. *Am J Epidemiol* 1996; 144:264-274. PMID: 8686695
78. Gardner CD, **Fortmann SP**, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. *JAMA* 1996; 276; 875-881. PMID: 8782636
79. Killen JD, **Fortmann SP**, Kraemer HC, Varady AN, Davis L, Newman, B. Interactive effects of depression symptoms, nicotine dependence and weight change on late smoking relapse. *J Consult Clinical Psychol* 1996; 64:1060-1067. PMID: 8916636
80. Oka RK, **Fortmann SP**, Varady AN. Differences in treatment of acute myocardial infarction by sex, age and other factors: the Stanford Five-City Project. *Am J Cardiol* 1996; 78:861-865. PMID: 8888655
81. Winkleby MA, Taylor CB, Jatulis D, **Fortmann SP**. Long-term effects of a cardiovascular disease prevention trial: The Stanford Five-City Project. *Am J Public Health* 1996; 86:1773-1779. PMID: 9003136; PMC1380732

82. Winkleby MA, Kraemer HC, Lin J, Jatulis D, **Fortmann SP**. Sociodemographic influences on Hispanic-White differences in blood pressure: The Stanford Five-City Project. *Public Health Reports* 1996; 111: 30-32. PMID: 8898768; PMC1381659
83. Wild SH, **Fortmann SP**, Marcovina SM. A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Throm Vasc Biol* 1997; 17:239-245. PMID: 9081676
84. Killen JD, **Fortmann SP**. Craving is associated with smoking relapse: Findings from three prospective studies. *Exp Clin Psychopharm* 1997; 2: 137-142. PMID: 9234050
85. Killen JD, **Fortmann SP**, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. *J Consult Clin Psych* 1997; 65: 663-672. PMID: 9256568
86. Albright CL, Bruce B, Howard-Pitney B, Winkleby MA, **Fortmann SP**. Development of a curriculum to lower dietary fat intake in a multiethnic population with low literacy skills. *J Nutr Educ* 1997;29:215-223. [No PMID or PMCID]
87. Stone EJ, Pearson TA, **Fortmann SP**, McKinlay JB. Community-based prevention trials: Challenges and directions for public health practice, policy, and research. *Ann Epidemiol* 1997;7 (S7): S113-S120. [No PMID or PMCID]
88. Winkleby MA, Howard-Pitney B, Albright CA, Bruce B, Kraemer HC, **Fortmann SP**. Predicting achievement of a low fat diet: A nutrition intervention for adults with low literacy skills *Prev Med* 1997; 26: 874-882. PMID: 9388800
89. Howard-Pitney B, Winkleby MA, Albright CL, Bruce B, **Fortmann SP**. The Stanford Nutrition Action Program: A dietary fat intervention for low literate adults. *Am J Public Health* 1997; 87(12): 1971-1976. PMID: 9431286; PMC1381239
90. Schooler C, Farquhar JW, **Fortmann SP**, Flora J. Synthesis of findings and issues from community prevention trials. *Ann Epidemiol* 1997; 7(7 Supplement); S54-S68. [No PMID or PMCID]
91. Tuomilehto J, for the WHO MONICA Project. Changes in cigarette smoking among adults in 35 populations in the mid-1980s. *Tob Control* 1998; 7:14-21. PMID: 9706749; PMC: 1759655
92. Ribisl KM, Winkleby MA, **Fortmann SP**, Flora JA. The interplay of socioeconomic status and ethnicity on Hispanic and White men's cardiovascular disease risk and health communication patterns. *Health Education Research* 1998; 13: 407-417. PMID: 10186451
93. Davis SK, Ahn DK, **Fortmann SP**, Farquhar JW. Determinants of cholesterol screening and treatment patterns: Insights for decision-makers. *Am J Prev Med* 1998;15(3):178-186. PMID: 9791635
94. Davis SK, **Fortmann SP**. Policy implications of health outcomes associated with level of cardiovascular disease risk reduction knowledge: Findings from a population-based cohort. *CVD Prevention* 1998;1:138-146. [No PMID or PMCID]
95. Greeno CG, Jackson C, Williams EL, **Fortmann SP**. The effect of perceived control over eating on the life satisfaction of women and men: Results from a community sample. *Int J Eat Disord* 1998; 24: 415-419. PMID: 9813766
96. Altman DG, Wheelis AY, McFarlane M, Lee H, **Fortmann SP**. The relationship between tobacco access and use among adolescents: A four community study. *Soc Sci Med* 1999; 48:759-775. PMID: 10190639

97. Daughton DM, **Fortmann SP**, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Rennard SI. The smoking cessation efficacy of varying doses of nicotine patch delivery systems four to five years post quit day. *Preventive Medicine* 1999; 28: 113-118. PMID: 10048102
98. Killen JD, **Fortmann SP**, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? *Exp Clin Psychopharm* 1999; 7(3): 226-33. PMID: 10472510
99. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, Broughton J, **Fortmann SP**, Leischow SJ, McKenna J, Rennard SI, Wadland W, Heatley S. Are higher doses of nicotine replacement more effective? *Nicotine Tob Res* 1999;1: 169-174. PMID: 11072398
100. Stamler J, **Fortmann SP**, Levy RI, Prineas RJ, Tell G. Primordial prevention of cardiovascular disease risk factors: panel summary. *Prev Med* 1999; 29: S130-S135. PMID: 10641831
101. Howard-Pitney B, Killen JD, **Fortmann SP**. Quitting Chew: Results from a randomized trial using nicotine patches. *Exp Clin Psychopharm* 1999; 7: 362-371. PMID: 10609971
102. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, **Fortmann S**, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. *Lancet* 2000; 355:675-687. PMID: 10703799
103. Gardner CD, Winkleby MA, **Fortmann SP**. Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1998–1994). *Am J Cardiol* 2000; 86: 299-304. PMID: 10922437
104. **Fortmann SP**, Varady AN. Effects of a community-wide health education program on cardiovascular disease morbidity and mortality: The Stanford Five-City Project. *Am J Epidemiol* 2000; 152: 316–323. PMID: 10968376
105. Gardner CD, Tribble DL, Young DR, Ahn D, **Fortmann SP**. Population frequency distributions of HDL, HDL<sub>2</sub>, and HDL<sub>3</sub> cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status and sex hormone use: The Stanford Five-City Project. *Prev Med* 2000; 31: 335-345. PMID: 11006058
106. Gardner CD, Tribble DL, Young DR, Ahn D, **Fortmann SP**. Associations of HDL, HDL<sub>2</sub>, and HDL<sub>3</sub> and apolipoproteins A-I and B with lifestyle factors in healthy women and men: The Stanford Five City Project. *Prev Med* 2000; 31: 346-356. PMID: 11006059
107. Killen JD, **Fortmann SP**, Schatzberg AF, Hayward C, Sussman L, Rothman M, Strausberg L, Varady A. Nicotine patch and paroxetine for smoking cessation. *J Consult Clin Psych* 2000; 68: 883–889. PMID: 11068974
108. Cooper R, Cutler J, Desvigne-Nickens P, **Fortmann SP**, Friedman L, Havlik R, Hogelin G, Manolio T, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the National Conference on CVD Prevention. *Circulation* 2000; 102:3137-3147. PMID: 11120707
109. Molarius A, Parsons RW, Dobson AJ, Kuulasmaa K, Moltchanov V, Evans A, **Fortmann SP**, Jamrozik KD, Sans S, Tuomilehto J and Puska P for the WHO MONICA

- Project. Trends in cigarette smoking in 36 populations from the early 1980s to the mid 1990s: Findings from the WHO MONICA Project. *Am J Public Health* 2001; 91:206-212. PMID: 11211628; PMC1446542
110. Howard-Pitney B, **Fortmann SP**, Killen JD. Generalizability of findings from a chewing tobacco cessation clinical trial. *Nicotine Tobacco Res* 2001; 3: 347-352. PMID: 11694202
  111. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, **Fortmann SP**. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. *Kidney Int* 2001; 60: 1106-1113. PMID: 11532106
  112. Palaniappan L, Carnethon M, **Fortmann SP**. Heterogeneity in the relationship between ethnicity, body mass index, and fasting insulin. *Diabetes Care* 2002; 25: 1351-1357. PMID: 12145234; PMC3121929
  113. Carnethon M, Palaniappan L, Burchfiel C, Brancati F, **Fortmann SP**. Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: The Atherosclerosis Risk in Communities Study, 1987–1998. *Diabetes Care* 2002; 25: 1358-1364. PMID: 12145235; PMC3132185
  114. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, **Fortmann SP**, Franklin BA, Goldstein LB, Greenland P, Grundy S, Hong Y, Houston Miller N, Lauer RM, Ockene IS, Sacco R, Sallis JF, Smith SC, Stone NJ, Taubert, KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. *Circulation* 2002; 106:388-391. PMID: 12119259
  115. Killen JD, **Fortmann SP**, Kraemer HC, Varady A. Do men outperform women in smoking cessation studies? Maybe - but not by much. *Exp Clin Psychopharmacol* 2002; 10: 295-301. PMID: 12233990
  116. Henriksen L, Flora JA, Feighery EC, **Fortmann SP**. Effects on youth of exposure to retail tobacco advertising. *J Applied Social Psych* 2002; 32: 1771-1789. [No PMID or PMCID]
  117. Henriksen L, **Fortmann SP**. Young adults' opinions of Philip Morris and its television advertising. *Tob Control* 2002; 11: 236-240. PMID: 12198275; PMC: 1759020
  118. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, **Fortmann SP**, Hong Y, Myers GL, Rifai N, Smith SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers For Disease Control and Prevention and the American Heart Association. *Circulation* 2003; 107:499-511. PMID: 12551878
  119. Killen JD, **Fortmann SP**, Schatzberg A, Hayward C, Varady A. Onset of major depression during treatment of nicotine dependence. *Addict Behav* 2003; 28: 461–470. PMID: 12628619
  120. Wrone EM, Carnethon MR, Palaniappan L, **Fortmann SP**. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. *Am J Kidney Dis* 2003; 41:580-587. PMID: 12612981
  121. Pearson TA, Bazzare T, Daniels SR, Fair JM, **Fortmann SP**, Franklin BA, Goldstein LB, Hong Y, Lauer RM, Mensah GA, Sallis JF, Smith S, Stone JNJ, Taubert KA. AHA Guide for improving cardiovascular health at the community level. A statement for public health

- practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. *Circulation* 2003; 107: 645-651. PMID: 12566381
122. Carnethon MR, Kinder LS, Fair JM, Stafford RS, **Fortmann SP**. Symptoms of depression as a risk factor for incident diabetes: Findings from the National Health and Nutrition Examination Epidemiologic Follow-Up Study, 1971-1992. *Am J Epidemiol* 2003;158:416-423. PMID: 12936896
  123. Palaniappan L, Carnethon, MR, **Fortmann SP**. Association between microalbuminuria and the metabolic syndrome: NHANES III. *Am J Hypertension*. 2003; 16:952-958. PMID: 14573334
  124. Hughes JR, Callas PW, High Dose Study Group [in alphabetical order: JO Broughton, **SP Fortmann**, DK Hatsukami, SA Heatley, JR Hughes, DE Jorenby, SJ Leischow, GR Lesmes, E Lichtenstein, JP McKenna, SR Rennard, RL Richmond and WC Wadland] Past alcohol problems do not predict worse smoking cessation outcomes. *Drug Alcohol Depend* 2003; 71:269-273. PMID: 12957344
  125. Luepker RV, Apple FS, Christenson RH, Crow RS, **Fortmann SP**, Goff D, Goldberg RJ, Hand MM, Jaffe AS, Julian DG, Levy D, Manolio T, Mendis S, Mensah G, Pajak A, Prineas RJ, Reddy KS, Roger VL, Rosamond WD, Shahar E, Sharrett AR, Sorlie P, Tunstall-Pedoe H. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: A statement from the AHA Council on Epidemiology and Prevention. *Circulation* 2003;108(20):2543-9. (Epub 2003 Nov 10.) PMID: 14610011
  126. Carnethon MR, **Fortmann SP**, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: The Atherosclerosis Risk in Communities Study, 1987 – 1998. *Am J Epidemiol* 2003; 158(11):1058-1067. PMID: 14630601
  127. Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, **Fortmann SP**, Haffner SM, Wagenknecht L. Predictors of incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. *Diabetes Care* 2004; 27: 788-793. PMID: 14988303
  128. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, **Fortmann SP**. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrology* 2004; 15: 420-426. PMID: 14747389
  129. Kinder LS, Carnethon MR, Palaniappan LP, King AC, **Fortmann SP**. Depression and the metabolic syndrome in young adults: Findings from the Third National Health and Nutrition Examination Survey. *Psychosomatic Med* 2004; 66: 316-322. PMID: 15184689
  130. Palaniappan L, Wang J, **Fortmann SP**. Coronary heart disease mortality for six ethnic groups in California 1990 – 2000. *Ann Epidemiol* 2004; 14: 499-506. PMID: 15310526
  131. Henriksen L, Feighery EC, Schleicher NC, Haladjian HH, **Fortmann SP**. Reaching youth at the point of sale: Cigarette marketing is more prevalent in stores where adolescents shop frequently. *Tob Control* 2004; 13: 315-318. PMID: 15333890; PMC1747887
  132. Henriksen L, Feighery EC, Wang Y, **Fortmann SP**. Association of retail tobacco marketing with adolescent smoking. *Am J Public Health* 2004; 94: 2081-2083. PMID: 15569957; PMC1448595

133. **Fortmann SP**, Ford E, Criqui MH, Folsom AR, Harris TB, Hong Y, Pearson TA, Siscovick D, Vinicor F, Wilson PF; CDC; AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and public health practice: report from the population science discussion group. *Circulation* 2004; 110: e554-9. PMID: 15611381
134. Jamison, RL, Hartigan P, Gaziano JM, **Fortmann SP**, Goldfarb DS, Haroldson JA, Kaufman J, Lavori P, McCully KS, Robinson K. Design and statistical issues in the Homocysteinemia in Kidney and End Stage Renal Disease (HOST) Study. *Clin Trials* 2004; 1:451-460. PMID: 16279283
135. Henriksen L, Dauphinee AL, Wang Y, **Fortmann SP**. Industry-sponsored anti-smoking ads and adolescent reactance: Test of a boomerang effect. *Tob Control* 2006; 15:13-18. PMID: 16436398; PMC2563637
136. Go AS, Iribarren C, Chandra M, Lathon PV, **Fortmann SP**, Quertermous, T, Hlatky MA for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Statin and  $\beta$ -blocker therapy and the initial presentation of coronary heart disease. *Ann Intern Med* 2006; 144: 229-238. PMID: 16490908
137. Madan A, Palaniappan L, Urizar G, Wang Y, **Fortmann SP**, Gould JB Sociocultural factors that affect pregnancy outcomes in two dissimilar immigrant groups in the United States. *J Pediatr* 2006; 148: 341-346. PMID: 16615964
138. Killen JD, **Fortmann SP**, Murphy GM, Hayward C, Arredondo CJ, Crompton D, Celio M, Abe L, Wang Y, Schatzberg AF. Extended treatment with bupropion for cigarette smoking cessation. *J Consult Clin Psych* 2006; 74: 286-294. PMID: 16649873
139. Taylor-Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, Iribarren C, Hlatky MA, Go AS, **Fortmann SP**. Validation of a new brief physical activity survey among men and women aged 60-69 years. *Am J Epidemiol*. 2006 Sep 15;164(6):598-606. PMID: 16840522
140. Feighery EC, Henriksen L, Wang Y, Schleicher NC, **Fortmann SP**. An evaluation of four measures of adolescents' exposure to cigarette marketing in stores. *Nic Tobac Res* 2006; 8: 751-759. PMID: 17132522
141. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, Hlatky MH, **Fortmann SP**. Metabolic syndrome and early-onset coronary artery disease: Is the whole greater than it's parts?. *J Am Coll Cardiol* 2006; 48:1800-1807. PMID: 17084253
142. Hurtz SQ, Henriksen L, Wang J, Feighery EC, **Fortmann SP**. The relationship between exposure to alcohol advertising in stores, owning alcohol promotional items, and adolescent alcohol use. *Alcohol Alcohol* 2007; 42:143-149. Epub 2007 Jan 11. PMID: 17218364; PMC: 4238906
143. Iribarren C, Husson G, Go AS, Lo JC, Fair JM, Rubin GD, Hlatky MA, **Fortmann SP**. Plasma leptin levels and coronary artery calcification in older adults. *J Clin Endocrinol Metab* 2007; 92:729-32. PMID: 17148566
144. Kennedy BS, **Fortmann SP**, Winkleby MA, Stafford RS. Elective and isolated carotid endarterectomy: health disparities in utilization and outcomes, but not readmission. *J Nat Med Assoc* 2007; 99:480-488. PMID: 17534005; PMC2576064
145. Taylor-Piliae RE, Haskell WL, Iribarren C, Norton LC, Mahbouda MH, Fair JM, Hlatky MA, Go AS, **Fortmann SP**. Clinical utility of the Stanford Brief Activity Survey in men

- and women with early-onset coronary artery disease. *J Cardioplum Rehab Prev* 2007;27:227-232. PMID: 17667019
146. Fair JM, Kiazand A, Varady AN, Mahbouba MH, Norton L, Rubin G, Iribarren C, Go AS, **Fortmann SP**. Ethnic differences in coronary artery calcium in a healthy cohort aged 60 to 69 years. *Am J Cardiol* 2007;100:981–985. PMID: 17826382
  147. Ardigo D, Assimes T, **Fortmann SP**, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. *Physiol Genomics* 2007;31:402-409 [first published Aug 14, 2007; doi:10.1152/physiolgenomics.00104.2007.] PMID: 17698927
  148. Hlatky MA, Quertermous T, Myers RM, Boothroyd DB, **Fortmann SP**, Iribarren C, Tabor HK, Assimes TL, Tibshirani RJ, Go AS. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. *Am Heart J* 2007;154:1035-1042. PMID: 18035072
  149. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, Southwick A, Myers RM, Iribarren C, **Fortmann SP**, Go AS, for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. *Am Heart J* 2007;154:1043-1051. PMID: 18035073
  150. Knowles JW, Wang H, Itakura H, Southwick A, Myers RM, Iribarren C, **Fortmann SP**, Quertermous T, Hlatky MA. Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. *Am Heart J* 2007; 154:1052-1058. PMID: 18035074; PMC4031914
  151. Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, **Fortmann SP**, Quertermous T, Hlatky MA for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? *Am Heart J* 2007;154:1059-1064. PMID: 18035075
  152. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML, Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS, Iribarren C, Hlatky MA, **Fortmann SP**, Myers RM, Kuhn H, Risch N, Quertermous T. A near null variant of 12/15-LOX encoded by a novel SNP in ALOX15 and the risk of coronary artery disease. *Atherosclerosis* 2008;198:136-144. [2007; Oct 22; Epub ahead of print] PMID:17959182; PMC2440699
  153. Henriksen L, Schleicher NC, Feighery EC, **Fortmann SP**. Receptivity to alcohol marketing predicts drinking initiation. *J Adolesc Health* 2008;42:28–35. PMCID: 18155027; PMC2175037
  154. Knowles JW, Assimes TL, Boerwinkle E, **Fortmann SP**, Go A, Grove M, Hlatky M, Iribarren C, Li J, Myers R, Risch N, Sidney S, Southwick A, Volcik KA, Quertermous T. Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. *BMC Medical Genetics* 2008; 9:23 (doi:10.1186/1471-2350-9-23); e-published 2 April 2008 (<http://www.biomedcentral.com/1471-2350/9/23>). PMID: 18384690; PMC2322963
  155. Burt JR, Iribarren C, Fair JM, Norton LC, Mahbouba M, Rubin GD, Hlatky MA, Go AS, **Fortmann SP**; for the Atherosclerotic Disease, Vascular Function and Genetic

- Epidemiology (ADVANCE) Study. Incidental findings on cardiac multidetector row computed tomography among healthy older adults: Prevalence and clinical correlates. *Arch Intern Med* 2008; 168:756-761. PMID: 18413559
156. **Fortmann SP**. Invited Commentary. Race, ethnicity, biology, and medical research: A modest proposal. *Curr Cardiovasc Risk Reports* 2008; 2:167-168. [No PMID or PMCID]
  157. Killen JD, **Fortmann SP**, Schatzberg AF, Arredondo C, Murphy G, Hayward C, Celio M, Crompton D, Fong D, Pandurangi M. Extended cognitive behavior therapy for cigarette smoking cessation. *Addiction* 2008; 103:1381-1390. PMID: 18855829; PMC4119230
  158. Kumanyika SK, Obarzanek E, Stettler N, Bell R, Field AE, **Fortmann SP**, Franklin BA, Gillman MW, Lewis CE, Poston WC 2nd, Stevens J, Hong Y; American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention. Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science). *Circulation* 2008 Jul 22;118(4):428-64. Epub 2008 Jun 30. PMID: 18591433
  159. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Lic J, Fair JM, Rubin GD, Sidney S, **Fortmann SP**, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE Study. *Hum Mol Genet* 2008;17:2320-2328. PMID: 18443000; PMC2733811
  160. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, **Fortmann SP**, Go A, Hlatky MA, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. *Hum Genet* 2008; 123: 399-408. PMID: 18369664; PMC4023692
  161. Terashima M, Nguyen PK, Rubin GD, Iribarren C, Courtney BK, Go AS, **Fortmann SP**, McConnell MV. Impaired coronary vasodilation by magnetic resonance angiography is associated with advanced coronary artery calcification. *J. Am. Coll. Cardiol. Img.* 2008;1;167-173. PMID: 19356424
  162. Henriksen L, Feighery EC, Schleicher NC, Cowling DW, Kline RS, **Fortmann SP**. Is adolescent smoking related to the density and proximity of tobacco outlets and retail cigarette advertising near schools? *Prev Med.* 2008 Aug; 47(2):210-4 [Epub 2008 Apr 29.] PMID: 18544462
  163. Iribarren C, Hlatky MA, Chandra M, Fair JM, Rubin GE, Go AS, Burt JR, **Fortmann SP** for the Atherosclerotic Disease, Vascular Function and Genetic Epidemiology (ADVANCE) Study. Incidental pulmonary nodules on cardiac computed tomography: prognosis and use. *Am J Med* 2008; 121:989-996. [PMID 18954846]
  164. Lee KL, **Fortmann SP**, Fair JM, Iribarren C, Rubin GD, Varady A, Go AS, Quertermous T, Hlatky MA. Insulin resistance independently predicts the progression of coronary artery calcification. *Am Heart J* 2009; 157:939-45. PMID: 19376325
  165. Dallongeville J, Iribarren C, Ferrières J, Lyon L, Evans A, Go AS, Arveiler D, **Fortmann SP**, Ducimetière P, Hlatky MA, Amouyel P, Southwick A, Quertermous T, Meirhaeghe A. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. *PPAR Research* vol. 2009, Article ID 543746, 11 pages, 2009 (doi:

- 10.1155/2009/543746) [ <http://www.hindawi.com/journals/ppar/2009/543746.html>.]  
PMID: 20016803; PMC: 2792957
166. Sydow K, **Fortmann SP**, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS. Distribution of asymmetric dimethylarginine among 980 healthy older adults of different ethnicities. *Clin Chem* 2010; 56:111-120 [epub 2009 Nov 5] PMID: 19892843
  167. Taylor-Piliae RE, Fair JM, Haskell WL, Varady AN, Iribarren C, Hlatky MA, Go AS, **Fortmann SP**. Validation of the Stanford Brief Activity Survey: Examining psychological factors and physical activity levels in older adults. *J Phys Activity Health* 2010; 7:87-94. PMID: 20231759; PMC4696759
  168. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nature Genetics* 2010; 42:441-447 [April 25, epub ahead of print; doi:10.1038/ng.571] PMID: 20418890; PMC2914600
  169. Bailey, SR, Fong, DM, Bryson, SW, **Fortmann, SP**, Killen, JD. Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy. *J Subst Abuse Treat* 2010; 39:150-156. [Jul 2: epub ahead of print] PMID: 20598833; PMC2910821
  170. Henriksen L, Schleicher NC, Feighery EC, **Fortmann SP**. A longitudinal study of exposure to retail cigarette advertising and smoking initiation. *Pediatrics* 2010 Aug; 126(2):232-8 [Epub 2010 Jul 19] PMID 20643725; PMC3046636
  171. Killen JD, **Fortmann SP**, Murphy G, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. *Addiction* 2010; 105:1660-1668. PMID: 20707784; PMC3749242
  172. Assimes TL, Holm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. (140 total authors). Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. *J Am Coll Cardiol* 2010; 56: 1552-1563. PMID: 20933357; PMC3084526a
  173. Terashima M, Nguyen PK, Rubin GD, Meyer CH, Shimakawa A, Nishimura DG, Ehara S, Iribarren C, Courtney BK, Go AS, Hlatky MA, **Fortmann SP**, McConnell MV. Right coronary wall CMR in the older asymptomatic ADVANCE cohort: Positive remodeling and associations with type 2 diabetes and coronary calcium. *J Cardiovas Mag Reson* 2010; 12:75 [doi:10.1186/1532-429X-12-75] PMID 21192815; PMC3022803
  174. Palaniappan LP, Wong EC, Shin JJ, **Fortmann SP**, Lauderdale DS. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. *Int J Obes (Lond)*. Mar 2011; 35(3):393-400. [Epub 3 August 2010; doi: 10.1038/ijo.2010.152] PMID: 20680014; PMC2989340
  175. Sarginson JE, Killen JD, Lazzeroni LC, **Fortmann SP**, Ryan HS, Schatzberg AF, Murphy GM. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B: Neuropsych Genet* 2011; 156(3):275-84. [Epub 2011 Jan 25] PMID: 21268243
  176. Taylor-Piliae RE, Fair JM, Varady AN, Hlatky MA, Norton LC, Iribarren C, Go AS, **Fortmann SP**. Ankle brachial index screening in asymptomatic older adults. *Am Heart J* 2011; 161: 979-985. PMID: 21570532; PMC4696757

177. Banerjee D, Wong EC, Shin J, **Fortmann SP**, Palaniappan L. Racial and ethnic variation in lipoprotein(a) levels among Asian Indian and Chinese patients. *J Lipids* 2011; vol. 2011, Article ID 291954, 6 pages; doi:10.1155/2011/291954. PMID: 21660301; PMC3108091
178. Wang EJ, Wong EC, Dixit AA, **Fortmann SP**, Linde RB, Palaniappan LP. Type 2 diabetes: Identifying high risk Asian American subgroups in a clinical population. *Diabetes Res Clin Pract* 2011;93:248-254 [epub ahead of print, June 10; doi: 10.1016/j.diabres.2011.05.025] PMID: 21665315; PMC3156287
179. Nguyen PK, Terashima M, Fair JM, Varady A, Taylor-Piliae RE, Iribarren I, Go AS, Haskell WL, **Fortmann SP**, McConnell MV. Physical activity in older subjects is associated with increased coronary vasodilation in the ADVANCE Study. *J Am Coll Cardiol Cardiovasc Imaging* 2011; 4 (6):622-9. PMID: 21679897
180. Lee KK, **Fortmann SP**, Varady A, Fair JM, Go AS, Quertermous T, Hlatky MA, Iribarren C. Racial variation in lipoprotein-associated phospholipase a2 in older adults. *BMC Cardiovasc Disord* 2011; 11(1):38. [doi: 10.1186/1471-2261-11-38] PMID: 21714927; PMC3146402
181. Bansal N, Hsu C, Chandra M, Iribarren C, **Fortmann SP**, Hlatky MA, Go AS. Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: a cohort study. *BMC Nephrol* 2011; 12:44 [doi:10.1186/1471-2369-12-44] PMID: 21917174; PMC3180367
182. Go AS, Bansal N, Chandra M, Lathon PV, **Fortmann SP**, Iribarren C, Hsu C, Hlatky MA, ADVANCE Study Investigators. Chronic kidney disease and risk of presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. *J Am Coll Cardiol* 2011; 58: 1600-07. PMID 21958887; PMC3184235
183. Henriksen L, Schleicher NC, Dauphineé A, **Fortmann SP**. Targeted advertising, promotion, and price for menthol cigarettes in California high school neighborhoods. *Nicotine Tobacco Res* 2012; 14:116-21 (Epub ahead of print, 24 June 2011: doi 10.1093/ntr/ntr122). PMID: 21705460; PMC3592564
184. Ambrosius WT, Polonsky T, Greenland P, Goff DC, Perdue LH, **Fortmann SP**, Margolis KL, Pajewski NM. Design of the Value of Imaging in Enhancing the Wellness (VIEW) of Your Heart Trial and the impact of uncertainty on power. *Clinical Trials* 2012; 9 (2): 232-246 (published online 14 February; DOI: 10.1177/1740774512436882). PMID: 22333998; PMC4475283
185. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BR, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Gabriel Steg P, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghide M, Filippatos G, Luepker RV, **Fortmann SP**, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Morais J, Aguiar C, Almahmeed W, Arnar DO, Barili F, Bloch KD, Bolger AF, Bøtker HE, Bozkurt B, Bugiardini R, Cannon C, de Lemos J, Eberli FR, Escobar E, Hlatky M, James S, Kern KB, Moliterno DJ, Mueller C,

- Neskovic AN, Pieske BM, Schulman SP, Storey RF, Taubert KA, Vranckx P, Wagner DR. Third universal definition of myocardial infarction. *Eur Heart J*. 2012; 33(20):2551-2567. [doi: 10.1093/eurheartj/ehs184] PMID: 22922414
186. Bhalla V, Zhao B, Azar K, Wang EJ, Choi S, Wong EC, **Fortmann SP**, Palaniappan L. Racial/Ethnic differences in the prevalence of proteinuric and non-proteinuric diabetic kidney disease. *Diabetes Care* 2013; 36(5):1215-1221 [epub 2012-Dec-13; doi: 10.2337/dc12-0951] PMID: 23238659; PMC3631839
187. Pearson TA, Palaniappan LP, Artinian NT, Carnethon MR, Criqui MH, Daniels SR, Fonarow GC, **Fortmann SP**, Franklin BA, Galloway JM, Goff DC, Heath GW, Frank ATH, Kris-Etherton PM, Labarthe DR, Murabito JM, Sacco RL, Sasson C, Turner MB. American Heart Association guide for improving cardiovascular health at the community level, 2013 update: A scientific statement for public health practitioners, healthcare providers, and health policy makers. *Circulation* 2013; 127(16):1730-53. [Epub 2013 Mar 21; doi: 10.1161/CIR.0b013e31828f8a94] PMID: 23519758; PMC35863531
188. Dauphineé AL; Doxey JR, Schleicher NC, **Fortmann SP**, Henriksen L. Racial differences in cigarette brand recognition and impact on youth smoking. *BMC Public Health* 2013; 13:170. PMID: 23442215; PMC3586353
189. **Fortmann SP**, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2013; 159(12):824-834. [Published online 2013/11/12, doi:10.7326/0003-4819-159-12-201312170-00729] PMID: 24217421; PMC: 3636284
190. Frank AT, Zhao B, Jose PO, Azar KM, **Fortmann SP**, Palaniappan LP. Racial/ethnic differences in dyslipidemia patterns. *Circulation* 2014; 129(5):570-579. [epub 2013/11/07, doi: 10.1161/CIRCULATIONAHA.113.005757] PMID: 24192801; PMC4212818
191. Nichols GA, Rosales AG, Perrin NA, **Fortmann SP**. The association between different A1C-based measures of glycemia and risk of cardiovascular disease hospitalization. *Diabetes Care* 2014; 37:167-172. [doi: 10.2337/dc13-1300] PMID: 23990520; PMC3818010
192. Gold R, Bailey SR, O'Malley JP, Hoopes MJ, Cowburn S, Marino M, Heintzman J, Nelson C, **Fortmann SP**, DeVoe JE. Estimating demand for care after a Medicaid expansion: Lessons from Oregon. *J Amb Care Management* 2014; 37(4):282-292 [epub 2014/03/18; doi: 10.1097/JAC.000000000000023] PMID: 24608921; PMC4172441
193. Zhao B, Jose PO, Pu J, Chung S, Ancheta IB, **Fortmann SP**, Palaniappan LP. Racial/Ethnic differences in hypertension prevalence, treatment, and control for outpatients in northern California 2010-2012. *Am J Hypertens* 2015; 28:631-9. [doi:10.1093/ajh/hpu189] PMID: 25352230; PMC4462650
194. Sarginson JE, Killen JD, Lazzeroni LC, **Fortmann SP**, Ryan HS, Ameli N, Schatzberg AF, Murphy GM. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. *Nicotine Tob Res* 2015; 17 (9): 1126-1133; [epub 2015 Jan 23; doi:10.1093/ntr/ntu273] PMID: 25572450; PMC4627483
195. Stevens VJ, Solberg LI, Bailey S, Kurtz SE, McBurnie MA, Priest E, Puro JE, Williams R, **Fortmann SP**, Hazlehurst BL. Assessing trends in tobacco cessation in diverse patient populations. *Nicotine Tob Res* 2016; 18 (3): 275-280 [epub 2015 April, doi: 10.1093/ntr/ntv092] PMID: 25921356; PMC5013819

196. Pu J, Romanelli R, Zhao BN, Azar K, Hastings KG, Nimbale N, **Fortmann SP**, Palaniappan LP. Dyslipidemia in special ethnic populations. *Cardiol Clin* 2015; 33(2): 325-333. PMID: 26893006
197. Sanders-Jackson A, Parikh N, Schleicher NC, **Fortmann SP**, Henriksen L. Convenience store visits by US adolescents: Rationale for healthier retail environments. *Health Place* 2015; 34: 63-66. PMID: 25955537; PMC4497830
198. Iribarren C, Chandra M, Rana JS, Hlatky MA, **Fortmann SP**, Quertermous T, Go AS. Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: The ADVANCE Study. *Clin Trials Regul Sci Cardiol* 2015; 5:1-7 (Epub 2015-08-25; doi: 10.1016/j.ctrsc.2015.08.002) [No PMID or PMCID]
199. Sanders-Jackson A, Schleicher N, **Fortmann SP**, Henriksen L. Effect of warning statements in e-cigarette advertisements: An experiment with young adults. *Addiction* 2015; [epub 2015 Sep 7; doi:10.1111/add.12838] PMID: 25557128; PMC5113715
200. Slight SP, Berner ES, Galanter B, Huff S, Lambert BL, Lannon C, Lehmann CU, McCourt BJ, McNamara M, Menachemi N, Payne TH, Spooner SA, Schiff GD, Wang TY, Akincigil A, Crystal S, **Fortmann SP**, Vandermeer ML, Bates DW. Meaningful use of electronic health records: Experiences from the field and future opportunities. *JMIR Med Inform* 2015; 3 (3): e30; published online 2015 Sep 18; doi 10.2196/medinform.4457. PMID: 26385598; PMC4704893
201. Patnode CD, Henderson JT, Thompson JH, Senger CA, **Fortmann SP**, Whitlock EP. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: A review of reviews for the U.S. Preventive Services Task Force. *Ann Intern Med* 2015; 163: 608-621; published online 2015 Sep 22; doi:10.7326/M15-0171. PMID 26389650
202. Boone-Heinonen J, Messer LC, **Fortmann SP**, Wallack L, Thornburg KL. From fatalism to mitigation: a conceptual framework for mitigating fetal programming of chronic disease by maternal obesity. *Prev Med* 2015 Dec; 81:451-459. PMID: 26522092; PMC4679670
203. Smith DH, Johnson ES, Boudreau DM, Cassidy-Bushrow AE, **Fortmann SP**, Greenlee RT, Gurwitz JH, Magid DJ, McNeal CJ, Reynolds K, Steinhubl SR, Thorp M, Tom JO, Vupputuri S, VanWormer JJ, Weinstein J, Yang X, Go AS, Sidney S. Comparative effectiveness of statin therapy in chronic kidney disease and acute myocardial infarction: A retrospective cohort study. *Am J Med* 2015; 128:1252 e1- e11. [doi:10.1016/j.amjmed.2015.06.030] PMID: 26169887; PMC4624042
204. Boone-Heinonen J, Markwardt S, **Fortmann SP**, Thornburg KL. Overcoming birth weight: can physical activity mitigate birth weight-related differences in adiposity? *Pediatr Obes* 2015. [doi:10.1111/ijpo.12040] PMID: 25988588; PMC4653090
205. Salfati E, Nandkeolyar S, **Fortmann SP**, Sidney S, Hlatky MA, Quertermous T, Go AS, Iribarren C, Herrington DM, Goldstein BA, Assimes TL. Susceptibility loci for clinical coronary artery disease and subclinical coronary atherosclerosis throughout the life course. *Circ Cardiovasc Genet* 2015; 8 (6):803-811 [doi: 0.1161/CIRCGENETICS.114.001071] PMID: 26417035; PMC4824193
206. NCD Risk Factor Collaboration (NCD-RisC); (400 authors). Trends in adult body mass index in 200 countries from 1975 to 2014: Pooled analysis of 1,698 population-based measurement studies with 19.2 million participants. *The Lancet* 2016; 387:1377-1396 [doi 10.1016/S0140-6736(16)30054-X]. PMID: 27115820

207. Iribarren C, Chandra M, Rana JS, Hlatky MA, **Fortmann SP**, Quertermous T, Go AS. High-sensitivity cardiac troponin-I and incident coronary heart disease among asymptomatic older adults. *Heart* 2016; 102 (15):1177-1182. [doi: 10.1136/heartjnl-2015-309136] [Epub ahead of print 2016 Mar 30] PMID; 27030599
208. Pu J, Romanelli R, Zhao BN, Azar K, Hastings KG, Nimbale N, **Fortmann SP**, Palaniappan LP. Dyslipidemia in special ethnic populations. *Endocrinol Metab Clin North Am* 2016; 45(1):205-216 (Reprinted from *Cardiology Clinics*, see citation 196 above). PMID: 26893006; PMC7251984
209. Bailey SR, Hoopes MJ, Marino M, Heintzman J, O'Malley JP, Hatch B, Angier H, **Fortmann SP**, DeVoe JE. Effect of gaining insurance coverage on smoking cessation in community health centers: A cohort study. *J Gen Intern Med* 2016; 31 (10): 1198-1205. [Published online 2016-06-24; doi: 10.1007/s11606-016-3781-4] PMID: 27329121; PMC5023615
210. NCD Risk Factor Collaboration (NCD-RisC); (400 authors). A century of trends in adult human height. *eLife* 2016; 5: e13410. [epub 2016 July 26; doi <http://dx.doi.org/10.7554/eLife.13410>] PMID: 27458798; PMC4961475
211. Leyro T, Crew EE, Bryson SW, Lembke A, Bailey SR, Prochaska JJ, Henriksen L, **Fortmann SP**, Killen JD, Killen DT, Hall S, David SP. Retrospective analysis of changing characteristics of treatment-seeking smokers: Implications for further reducing smoking prevalence. *BMJ Open* 2016;6: e010960 [doi:10.1136/bmjopen-2015-010960] PMID: 27357195; PMC4932265
212. Schleicher NC, Johnson TO, **Fortmann SP**, Henriksen L. Tobacco outlet density near home and school: Associations with smoking and norms among US teens. *Prev Med* 2016; 91: 287–293. [doi: 10.1016/j.ypmed.2016.08.027] PMID: 27569829; PMC5065244
213. Bosworth HB, **Fortmann SP**, Kuntz J, Zullig LL, Mendys P, Safford M, Phansalkar S, Wang T, Rumpitz MH. Recommendations for providers on person-centered approaches to assess and improve medication adherence. *J Gen Intern Med.* 2017;32(1):93-100. [epub 2016 Sep 6; DOI: 10.1007/s11606-016-3851-7] PMID: 27599489; PMC5215159
214. Gurwitz JH, Go AS, **Fortmann SP**: Statins for primary prevention in older adults: Uncertainty and the need for more evidence. *JAMA Viewpoint* 2016; 316 (19): 1971-2. PMID: 27838724; PMC5429025
215. NCD Risk Factor Collaboration (NCD-RisC), Zhou B, Bentham J, et al. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19.1 million participants. *The Lancet.* 2017;389(10064):37-55. 2016 November 15 doi 10.1016/S0140-6736(16)31919-5 [SPF one of 400+ authors] PMID: 27838724; PMC5429025
216. Nichols GA, Reynolds K, Olufade TO, Kimes TM, O'Keeffe-Rosetti M, Sapp DS, Anzalone D, **Fortmann SP**. Effect of combination cholesterol-lowering therapy and triglyceride-lowering therapy on medical costs in patients with type 2 diabetes mellitus. *Am J Cardiology* 2017; 119(3): 410–415. [<http://dx.doi.org/10.1016/j.amjcard.2016.10.029>]; PMID: 27890243
217. Reynolds K, Go AS, Leong TK, Boudreau DM, Cassidy-Bushrow AE, **Fortmann SP**, Goldberg RJ, Gurwitz JH, Magid DJ, Margolis KL, McNeal CJ, Newton KM, Novotny R, Quesenberry CP, Rosamond WD, Smith DH, VanWormer JJ, Vupputuri S, Waring SC, Williams MS, Sidney S. Trends in incidence of hospitalized acute myocardial infarction in the Cardiovascular Research Network (CVRN). *Am J Med* 2017; 130 (3):

- 317–327 [doi: <http://dx.doi.org/10.1016/j.amjmed.2016.09.014>] PMID: 27751900; PMC5318252
218. Bailey SR, Heintzman J, Marino M, Jacob L, Puro J, DeVoe JE, Burdick T, Hazlehurst B, Cohen DJ, **Fortmann SP**. Smoking cessation assistance: Before and after stage 1 meaningful use implementation. *Am J Prev Med* 2017; 53(2): 192–200 [published online 29-MAR-2017; doi 10.1016/j.amepre.2017.02.006] PMID: 28365090; PMC5522621
219. Henriksen L, Schleicher NC, Ababseh K, Johnson TO, **Fortmann SP**. Marijuana as “concept” flavor for cigar products in stores near schools. *Tob Control* 2018; 27 (5): 585–588 [published online October 2017; doi: 10.1136/tobaccocontrol-2017-053961] PMID: 29025999; PMC5897220.
220. Bailey S, Stevens VJ, **Fortmann SP**, Kurtz SE, McBurnie MA, Priest E, Puro J, Solberg LI, Schweitzer R, Masica AL, Hazlehurst B. Long term outcomes from repeated smoking cessation assistance in routine primary care. *Am J Health Promotion* 2018; 32 (7): 1582–1590 [published online March 2018; DOI: 10.1177/0890117118761886] PMID: 29534598; PMC6342013.
221. Singh S, Ziemann S, Go AS, **Fortmann SP**, Wenger NK, Fleg JL, Radziszewska B, Stone NJ, Zoungas S, Gurwitz JH. Statins for primary prevention in Older Adults—Moving toward evidence-based decision-making. *J Am Geriatrics Society* 2018; 66:2188–2196 [published online October 2018; 10.1111/jgs.15449] PMID: 30277567; PMC6741349.
222. Young DR, Nguyen MK, Yamamoto A, Pomichowski M, Cornejo M, Paz S, Coleman KJ, Sallis RE, Fortmann SP. Telephone-based motivational interviewing versus usual care in primary care to increase physical activity: A randomized pilot study. *Pilot and Feasibility Studies* 2019; 5:6 [<https://doi.org/10.1186/s40814-019-0390-0>] [Full text: <https://rdcu.be/bg75d;>] PMID: 30675373; PMC6332699
223. Frank LD, Kuntz JL, Chapman JE, Fos EH, Dickerson JF, Meenan RT, Saelens BE, Young DR, Boone-Heinonen J, **Fortmann SP**. The health and economic effects of light rail lines: Design and methods of a natural experiment. *BMC Public Health* 2019; 19:200 [<https://doi.org/10.1186/s12889-019-6518-6>]. [<https://rdcu.be/bm425>] PMID: 30770737; PMC6377787.
224. **Fortmann SP**, Bailey SR, Brooks NB, Hitsman B, Rittner SS, Gillespie SE, Hill CN, Leo MC, Crawford PM, Hu W, King DS, O’Cleirigh C, Puro JE, McBurnie MA. Trends in smoking documentation in safety net clinics. *Health Services Research* 2020; 55:170–177. [<https://doi.org/10.1111/1475-6773.13259>] PMID: 31930738; [PMC7080378](https://doi.org/10.1111/1475-6773.13259).
225. Falasinnu T, Chaichian Y, Li J, Chung S, Waitzfelder BE, Fortmann SP, Palaniappan L, Simard JF. Does SLE widen or narrow race/ethnic disparities in the risk of five comorbid conditions? Evidence from a community-based outpatient care system. *Lupus* 2019; 28(14):1619-1627. [doi: 10.1177/0961203319884646; Epub 2019 Oct 29] PMID: 31660790; PMC8459796.
226. Sivitz WI, Phillips LS, Wexler DJ, **Fortmann SP**, Camp AW, Titkin M, Perez M, Craig J, Hollander PA, Cherrington A, Aroda VR, Tan MH, Krakoff J, Rasouli N, Younes N, Butera NM, and the GRADE Research Group. Optimization of metformin in the GRADE cohort: Effect on glycemia and body weight. *Diabetes Care* 2020; 43: 940-47 [Epub Mar 7; doi: 10.2337/dc19-1769.] PMID:32139384; PMC7171946.
227. Ambrosy A, Fitzpatrick J, Tabada G, Gurwitz J, Artz A, Schrier S, Rao S, Reynolds K, Smith D, Peterson P, **Fortmann SP**, Hee Sung SH, Cohen H, and Go A. A reduced transferrin saturation is independently associated with excess morbidity and mortality in

- older adults with heart failure and incident anemia. *International J Cardiol* 2020 (Mar 12); 309: 95-99 [Epub: 10.1016/j.ijcard.2020.03.020] PMID: 32201101
228. Greenland P, Michos ED, Redmond N, Fine LJ, Alexander KP, Ambrosius WT, Bibbins-Domingo K, Blaha MJ, Blankenstein R, **Fortmann SP**, Khera A, Lloyd-Jones DM, Maron DJ, Min JK, Muhlestein JB, Nasir K, Sterling MR, Thanassoulis G. Primary prevention trial designs using coronary imaging: A National Heart, Lung, and Blood Institute workshop. *JACC Cardiovascular Imaging* 2021 Jul;14(7):1454-1465.2020 [Sep 11:S1936-878X(20)30650-1; doi: 10.1016/j.jcmg.2020.06.042. Epub ahead of print.] PMID: 32950442.
229. Kuntz J, Young DR, Saelens BE, Meenan RT, Frank LD, Keast E, Dickerson JF, **Fortmann SP**. Validity of the exercise vital sign tool to assess physical activity. *Am J Prev Med* 2021 Jun; 60(6):866-872. [Online ahead of print; doi: 10.1016/j.amepre.2021.01.012.] PMID: 33781618; PMC8154650 (available on 2022-06-01).
230. Henriksen L, Schleicher N, **Fortmann SP**. Menthol cigarettes in black neighborhoods: Still cheaper after all these years (Letter). *Tobacco Control* [Epub ahead of print 12 August 2021; doi 10.1136/tobaccocontrol-2021-056758.] PMID: 34385403; PMC8837722 (available on 2023-02-12).
231. Fitzpatrick SL, Mayhew M, Catlin CL, Firemark A, Groß I, Nyongesa DB, O’Keeffe-Rosetti M, Rawlings AM, Smith DH, Smith N, Stevens VJ, Vollmer WM, **Fortmann SP**. Evaluating the implementation of digital and in-person diabetes prevention programs in a large, integrated health system: Natural experiment study design. *Perm J* 2021; 26(1): 21-31 [Epub 12/13/2021; <https://doi.org/10.7812/TPP/21.056>].
232. Saelens BE, Meenan RT, Keast EM, Frank LD, Young DR, Kuntz JL, Dickerson JF, **Fortmann SP**. Transit use and health care costs: A cross-sectional analysis. *J Transport & Health* 2022; 24: 101292 [published online 24 Nov 2021; <https://doi.org/10.1016/j.jth.2021.101294>] PMID: 34926159; PMC8682981].
233. Wali B, Frank LD, Young DR, Meenan RT, Saelens BE, Dickerson JF, **Fortmann SP**. Causal evaluation of the health effects of light rail line: A natural experiment. *J Transport & Health* 2022 (Mar); 24: 101292 [published online 10 Dec 2021; <https://doi.org/10.1016/j.jth.2021.101292>]. PMID: 35096526; PMC8797061.
234. Shortreed SM, Gray R, Akosile MA, Walker RL, Fuller S, Temposky L, **Fortmann SP**, Albertson-Junkans L, Floyd JS, Bayliss EA, Harrington LB, Lee MH, Dublin S. Increased COVID-19 infection risk drives racial and ethnic disparities in severe COVID-19 outcomes. *Journal of Racial and Ethnic Health Disparities* 2022; 1-11 [published online 24 January 2022; <https://doi.org/10.1007/s40615-021-01205-2>]. PMID: 35072944; PMC8785693.
235. Fitzpatrick SL, Mayhew M, Rawlings AM, Smith N, Nyongesa DB, Vollmer WM, Stevens VJ, Grall SK, **Fortmann SP**. Evaluating the implementation of a digital diabetes prevention program in an integrated healthcare delivery system among older adults: Results from a natural experiment. *Clinical Diabetes* 2022; 40(3): 345-353 [<https://doi.org/10.2337/cd21-0114>].
236. Meenan RT, Frank LD, Saelens BE, Young DR, Kuntz JL, Dickerson JF, Wali B, Keast EM, **Fortmann SP**. Effects of an urban light rail line on health care utilization and cost: A pre-post assessment. *Transport Policy* 2022; 123:112-120 [<https://doi.org/10.1016/j.tranpol.2022.05.005>].

237. Smith DH, O’Keeffe-Rosetti M, Fitzpatrick SL, Mayhew M, Firemark AJ, Größ I, Nyongesa DB, Rawlings AM, Smith N, Dickerson JF, Stevens VJ, Vollmer WM, **Fortmann SP**. Costs and cost-effectiveness of implementing a digital diabetes prevention program in a large, integrated health system. *The Permanente Journal* 2022; 26(3): 74–82 [Epub 2022/08/31: doi: 10.7812/TPP/22.029].
238. Wali B, Frank LD, Young DR, Saelens BE, Meenan RT, Dickerson JF, Keast E, Kuntz JL, **Fortmann SP**. Pathways from built environment to health care costs: Linking objectively measured built environment with physical activity and health care. *Environment & Behavior* 2022; 54 (4): 747-782 [<https://doi.org/10.1177/00139165221083291>].
239. GRADE Study Research Group, Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, Cherrington AL, **Fortmann SP**, Green JB, Kahn SE, Kirkman MS, Krause-Steinrauf H, Larkin ME, Phillips LS, Pop-Busui R, Steffes M, Tiktin M, Tripputi M, Wexler DJ, Younes N. Glycemia reduction in type 2 diabetes: Micro- and cardiovascular outcomes. *N Engl J Med* 2022; 387(12): 1075–1088 [doi 10.1056/NEJMoa2200436].
240. Mayhew M, Smith N, **Fortmann SP**, Fitzpatrick SL. Mental health diagnosis attenuates weight loss among older adults in a digital diabetes prevention program. *Obesity Science & Practice* 2022; 1–7 [Epub 2022 Nov 01: doi: <http://doi.org/10.1002/osp4.644>].
241. Tisminetzky M, Gurwitz J, Tabada GH, Reynolds K, **Fortmann SP**, Garcia E, Pham T, Goldberg R, Go AS. Adverse events after initiating angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in individuals with heart failure and multimorbidity. *Am J Med* 2022; [Epub 2022/09/05 doi: 10.1016/j.amjmed.2022.08.010; PMID 36058306]
242. Floyd JS, Walker RL, Kuntz JL, Shortreed SM, **Fortmann SP**, Bayless EA, Harrington LB, Fuller S, Albertson-Junkans LH, Powers JD, Lee, MH, Temposky LA, Dublin S. Association Between Diabetes Severity and Risks of COVID-19 Infection and Outcomes. *J Gen Intern Med* 2023; 1-9; [Epub: 2023/02/17; 10.1007/s11606-023-08076-9; PMC9933797; PMID: 36795328]
243. Waitzfelder B, Palaniappan L, Varga A, Frankland TB, Li J, Daida YG, Kaholokula JK, Bacong AM, Rawlings AM, Chung S, Howick C, **Fortmann SP**. Prevalence of cardiovascular disease among Asian, Pacific Islander and multi-race populations in Hawai’i and California. *BMC Public Health* 2023; 23:885 (<https://rdcu.be/dccNX>) [<https://doi.org/10.1186/s12889-023-15795-5>].
244. Cherrington A, Krause-Steinrauf H, Aroda V, Buse J, Fattaleh B, **Fortmann SP**, Hall S, Hox S, Kuhn A, Killean T, Loveland A, Phillips L, Jackson A, Waltje A, McKee DM. Use of the electronic health record and other recruitment strategies in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) multi-center clinical trial. *Clinical Trials* 2023; 20 (5): 546-558 [<https://doi.org/10.1177/17407745231175919>].
245. Babu TM, Feldstein LR, Saydah S, et al. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design. *BMJ Open*. 2023;13(7):e071446. [Epub: 2023/07/15; 10.1136/bmjopen-2022-071446; PMC10350906]
246. Banerji MA, Buse JB, Younes N, Krause-Steinrauf H, Ghazi A, Lee M, Park J, Pop-Busui R, Underkofler C, **Fortmann SP**. Mortality in the Glycemia Reduction Approaches in Type 2 Diabetes (GRADE) Study: A Comparative Effectiveness

- Randomized Clinical Trial. *Diabetes Care* 2024; [Epub ahead of print: 2024 Jan 29;dc231782. DOI: 10.2337/dc23-1782. PMID: 38285957].
247. Wali B, Frank LD, Saelens BE, Young DR, Meenan RT, Dickerson JF, Keast EM, **Fortmann SP**. Associations of walkability, regional and transit accessibility around home and workplace with active and sedentary travel. *Journal of Transport Geography*. 2024;116:103776. [Epub: <https://doi.org/10.1016/j.jtrangeo.2023.103776>]
248. Boone-Heinonen J, Scott K, Springer R, Schmidt T, Vesco KK, Booman A, Dinh D, **Fortmann SP**, Foster BA, Hauschildt J, Liu S, O'Malley J, Palma A, Snowden JM, Stratton K, Tran ST. Pregnancy health in a multi-state U.S. population of safety net patients and their children: PROMISE Cohort design and baseline characteristics. *BMC Public Health* 2024: 886 [online 2024-03-23: <https://doi.org/10.1186/s12889-024-18257-8>]
249. Harrington LB, Powers JD, Bayliss EA, **Fortmann SP**, Shortreed SM, Walker RL, Floyd JS, Kuntz J, Fuller S, Albertson-Junkans L, Lee MH, Temposky LA, Dublin S. Current use of estrogen-containing oral contraceptives or hormone therapy and risk of COVID-19 infection and hospitalization: a population-based cohort study. *Am J Epidemiology* 2024. [Epub 16 May 2024: 10.1093/aje/kwae066].
250. Bacong AM, Gibbs S, Rosales AG, Frankland TB, Li J, Daida YG, **Fortmann SP**, Palaniappan L. Obesity disparities among adult single-race and multiracial Asian and Pacific Islander populations. *JAMA Network Open* 2024;7(3):e240734. [Epub: 2024/03/19; 10.1001/jamanetworkopen.2024.0734; PMC10951735].
251. Li J, Daida YG, Bacong AM, Rosales AG, Frankland TB, Varga A, Chung S, **Fortmann SP**, Waitzfelder B, Palaniappan L. Trends in cigarette smoking and the risk of incident cardiovascular disease among Asian American, Pacific Islander, and multiracial populations. *Am J Prev Cardiol* 2024;19:100688. [Epub 22 June 2024: <https://doi.org/10.1016/j.ajpc.2024.100688>].
252. Young DR, Sidell MA, Jimenez JJ, Fauresviun E, Tayag JN, Wang ML, Cohen DA, Xiang A, **Fortmann SP**. Baseline characteristics of self-determination theory constructs and accelerometer-derived physical activity: The Exercise Promotion in Primary Care (EPPC) Trial. *J Community Med Public Health* 2024; 8: 471. DOI: <https://doi.org/10.29011/2577-2228.100471>
253. Kuntz JL, Babu TM, Feldstein LR, Englund JA, Frivold CJ, Groom HC, Smith N, Varga AM, Cox SN, **Fortmann SP**, Mularski RA, Schmidt MA, Weil AA, Boisvert CL, Hollcroft M, Hatchie TL, Lo N, MacMillan MP, Reich S, Yetz N, Chu HY, Naleway AL. Knowledge About Respiratory Syncytial Virus and Acceptance of Infant Monoclonal Antibody for RSV and RSV Vaccination During Pregnancy. *Pediatr Infect Dis J*. 2025; 44(2S): S162-S166. [Epub: 20250214; 10.1097/INF.0000000000004566;]
254. Go AS, Tabada GH, Sung SH, Reynolds K, Scott RD, Garg AX, **Fortmann SP**, Lo JC, Young JD, Solomon MD, Rana JS. Improving Atherosclerotic Cardiovascular Disease Risk Prediction in Ethnically Diverse North American Populations. *Am J Med* (submitted September 2023).
255. Daida YG, Rosales AG, Frankland TB, Bacong AM, Waitzfelder B, Li J, Kaholokula LK, Palaniappan L, **Fortmann SP**. Differences in coronary heart disease and stroke incidence among single-race and multiracial Asians and Pacific Islander Subgroups in Hawaii and California: A retrospective cohort study. *J Am Heart Assoc*. 2025; 14:e039076 [DOI: 10.1161/JAHA.124.039076].

256. Wexler DJ, Garvey WT, Ghosh A, Kazemi EJ, Krause-Steinrauf H, Ahmann AJ, Brown-Friday J, Casula S, Cherrington AL, Elasy TA, **Fortmann SP**, Krakoff JA, Mudaliar S, Tiktin M, Younes N, Group GSR. Weight Gain Was Associated with Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial. *Diabetes Care*. 2025. [Epub: 20250423; 10.2337/dc24-2825; ].
257. Bacong AM, Frankland TB, Rosales AG, Gibbs S, Li J, Daida Y, **Fortmann SP**, and Palaniappan L.. Increased Risk of Myocardial Infarction and Stroke Among Multiracial Asian and Pacific Islander Adults with Diabetes: Evidence from Electronic Health Records. *J Am Heart Assoc*. 2026;10.1161/JAHA.125.043657:e043657. 2026-04-22; [doi 10.1161/JAHA.125.043657; PMID:42017327].
258. Groom H, Kuntz JL, Varga AM, Smith N. Coto E, et al. Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine. *Vaccine* 2025; 63: 127618 [https://doi.org/10.1016/j.vaccine.2025.127618; epub 23 August 2025].
259. Young D, Preciado M, Soto V, Edith Fauresviu E, Jimenez JJ, Sidell MA, Tayag JN, Arriola F, Paz SR, Cohen DA, Xiang AH, Wang ML, O’Keeffe Rosetti M, **Fortmann SP**. Sociodemographic Characteristics of Patients throughout the Recruitment Process into a Randomized, Controlled Behavioral Trial. *Trials* 2025 26:519 (doi.,org/10.1186/s13063-025-09225-7) [PMID 41254652].

## 2. Non-peer-reviewed articles

1. **Fortmann SP**. Abortion and medicine. The *Pharos* of Alpha Omega Alpha 1975;38:25-29.
2. Sallis JF, **Fortmann SP**, Solomon DS, Farquhar JW. [Letter] Increasing returns of physician surveys. *Am J Public Health* 1984; 74 (9): 1043. [PMID 6465406; PMC1651776]
3. Rudd P, Price MG, Graham LE, **Fortmann SP**. [Letter] More on labeling of hypertensive patients. *N Engl J Med* 1984; 310 (17): 1126. [PMID 6709003]
4. Sallis JF, Hill RD, **Fortmann SP**, Flora JA. Heart health behavior change at the worksite: Cardiovascular risk reduction. *Progress in Behavior Modification* 1986;20:161-97.
5. Rudd P, **Fortmann SP**. [Comment] Some cautions in labeling effects. *Arch Intern Med* 1991; 151 (11): 2313.
6. Frank E, **Fortmann SP**, Causey DD. The impact of smoking cessation on cardiovascular risk. *Modern Medicine* 1994;62:3-10.
7. **Fortmann SP**. Smoking: No time for complacency [Editorial]. *Cardiovascular Risk Factors* 1996; 6:123-125.
8. **Fortmann SP**, Marcovina SM. Lipoprotein(a), a clinically elusive lipoprotein particle [Editorial]. *Circulation* 1997; 95: 295-296.
9. **Fortmann SP**. A refresher on the management of common lipid disorders. *The Chronicle of Cardiovascular and Internal Medicine* 1997 (December); 1 (2): 11-12.

10. **Fortmann SP.** Race, ethnicity, biology, and medical research: A modest proposal [Invited Commentary]. *Curr Cardiovasc Risk Reports* (accepted December 2007)

### 3. Book

**Fortmann SP, Breitrose PE.** *The Blood Pressure Book*. Palo Alto, CA: Bull Publishing Company, 1996, 2001 (Second Edition), 2006 (Third Edition). Third Edition translated and issued in Spanish in 2006, *Libro de la presión sanguínea*.

### 4. Book Chapters

1. Hulley SB, **Fortmann SP.** Clinical trials of changing behavior to prevent cardiovascular disease. In Weiss SM, Herd JA, Fox BH, (eds). *Perspectives in Behavioral Medicine*. New York: Academic Press, 1980:89-98.
2. Farquhar JW, **Fortmann SP,** Wood PD, Haskell WL. Community studies of cardiovascular disease prevention. In Kaplan NM, Stamler J, (eds). *Prevention of Coronary Heart Disease*. Philadelphia: WB Saunders Co., 1983:170-181.
3. **Fortmann SP.** Nutritional factors in chronic disease. In: Haller EW, Cotton GE, (eds). *Proceedings of the Conference on Nutrition in the Young and the Elderly*. Lexington, MA: The Collamore Press, 1983:173-188.
4. Farquhar JW, **Fortmann SP,** Maccoby N, Wood PD, Haskell WL, Taylor CB, et al. The Stanford Five-City Project: An overview. In Matarazzo JD, Miller NE, Weiss SM, Herd JA, Weiss SM (eds). *Behavioral Health: A Handbook of Health Enhancement and Disease Prevention*. Silver Spring, MD: John Wiley & Sons, Inc; 1984: 1154-65.
5. Taylor CB, **Fortmann SP.** Essential hypertension. In Dorfman W, Cristofar L (eds). *Psychosomatic Illness Review*. New York: Macmillan Publishing Company, 1985: 90-106.
6. Rudd P, Price MG, Graham LE, **Fortmann SP,** Beilstein B, Tarbell S, Bacchetti P. Impact of hypertensive labeling on worker absenteeism and psychosocial dysfunction. In Rosenfeld JB, Silverberg DS, Viskoper R (eds). *Hypertension Control in the Community*. London: John Libby & Co., Ltd., 1985: 62-66.
7. Sallis JF, Hill RD, **Fortmann SP,** Flora JA. Health behavior change at the worksite: cardiovascular risk reduction. In Herson M, Eisler RM, Miller PM (eds). *Progress in Behavior Modification* Vol 20: 161-197. Elsevier, 1986. [PMID 3517827]
8. Farquhar JW, **Fortmann SP.** Problems with implementing public intervention strategies. In Lundgarde F (ed): *Proceedings of the First Ernhold Lundstrom Symposium: Genetic Susceptibility to Environmental Factors - a Challenge for Public Intervention*. Stockholm, Sweden: Almqvist & Wiskell, 1988.
9. Committee on Criteria and Methods of the Council on Epidemiology, American Heart Association. *Annotated bibliography of epidemiological methods of cardiovascular research*. Dallas, TX: American Heart Association, 1989. [Dr. Fortmann chaired the committee and edited the monograph]
10. Farquhar JW, **Fortmann SP,** Flora JA, Maccoby N. Methods of communication to influence behaviour. In Holland WW, Detels R, Knox G, (eds). *Oxford Textbook of Public Health*. New York: Oxford University Press, 1991:331-344.

11. **Fortmann SP**, Maron DJ. Disorders of lipid metabolism. In Dale, DC, Federman DD (eds): *Scientific American Medicine* 1991; Section 9, Subsection II: 1-24. [Revised and reissued, 1993, 1996, 1998]
12. Farquhar JW, **Fortmann SP**. Phases for developing community trials: Lessons for control of alcohol problems from research in cardiovascular disease, cancer, and adolescent health. In Holder HD, Howard JM (eds). *Community Prevention Trials for Alcohol Problems: Methodological Issues*. Westport, CT: Praeger Publishers, 1992: 59-75
13. Flora JA, Jatulis D, Jackson C, **Fortmann SP**. The Stanford Five-City Heart Disease Prevention Project. In Backer TE, Rogers E (eds). *Organizational aspects of health communication campaigns: What works?* Newbury Park, CA: Sage Publications, 1993: 101-128.
14. **Fortmann SP**. Controlling high blood pressure with exercise. In: *Fresh Start: The Stanford Medical School Health and Fitness Program*. San Francisco, CA: KQED Books and Video, 1996: 189-199.
15. **Fortmann SP**, Shane B, Motulsky A. Summary and future directions for epidemiological, preventive, and basic research. In Robinson K (ed). *Homocysteine and Vascular Disease*. Dordrecht, The Netherlands and Norwell, MA: Kluwer Academic Publishers, 2000: 431-436.
16. Farquhar JW, **Fortmann SP**. Community-based Health Promotion. In Ahrens W, Pigeot I (eds.) *Handbook of Epidemiology*. New York: Springer, 2005: 1305-1323.

## 5. Recent Abstracts (6 of 109)

1. Wali, B., Frank, L., Young, D., Meenan, R., Saelens, B., Dickerson, J., **Fortmann, S.** (2022). Causal evaluation of the health effects of light rail line: A longitudinal analysis of objectively assessed active travel and health care costs. Presented at the 101st Annual Meeting of the Transportation Research Board, Washington DC, USA. TRBAM-22-01481.
2. Bacong AM, Gibbs S, Frankland TB, Rosales AG, Li J, Daida YG, **Fortmann SP**, Palaniappan L. Obesity disparities among multiracial Asian American and Pacific Islander adults. Presented at the American Diabetes Association, June 2023
3. Gibbs S, Bacong AM, Rosales AG, Frankland TB, Li J, Daida YG, Waitzfelder B, **Fortmann SP**, Palaniappan L. Heterogeneity in the association of diet and obesity in Asian, Pacific Islander, and Multiracial People. Presented at the American Diabetes Association, June 2023
4. Gibbs SL, Bacong AM, Amaturio L, Frankland TB, Rosales AG, Li J, Daida YG, **Fortmann SP**, Palaniappan L. Investigating the Relationship Between Cardiovascular Diseases and Major Depressive Disorder among Asians and Pacific Islanders. Poster presented at the American Heart Association Epidemiology Lifestyles Sessions, 19 March 2024, Chicago, IL
5. Amaturio L, Bacong AM, Gibbs S, Rosales AG, Frankland TB, Li J, Daida YG, **Fortmann SP**, Palaniappan L. Nativity explains disparities in provider experience scores among Asian and Pacific Islander patients with and without cardiovascular disease. Poster presented at the American Heart Association Epidemiology Lifestyles Sessions, 19 March 2024, Chicago, IL.

6. Bacong AM, Frankland TB, Li J, Daida YG, **Fortmann SP**, Palaniappan LP. Performance of Pooled Cohort Equations and the AHA Predicting Risk of cardiovascular EVENTS Equations Among Multiracial Asian and Pacific Islander People. Moderated Poster Presentation at the American Heart Association (AHA) Scientific Sessions, November 2024, Chicago, IL